var title_f20_42_21152="Ablative fractional resurfacing - before and after";
var content_f20_42_21152=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F81643&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F81643&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 531px\">",
"   <div class=\"ttl\">",
"    Improvement in facial wrinkles following ablative fractional laser resurfacing",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 511px; height: 211px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This patient was treated with a fractional CO",
"    <sub>",
"     2",
"    </sub>",
"    laser for facial wrinkles. She is shown before (A) and after treatment (B).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_42_21152=[""].join("\n");
var outline_f20_42_21152=null;
var title_f20_42_21153="External rotation ankle stress test";
var content_f20_42_21153=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F57674&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F57674&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    External rotation stress test",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A provocative test for syndesmotic injury. The examiner supports the lateral fibula and tibia with one hand and gently forces external rotation with the other. Pain at the distal syndesmosis (area of pain indicated by the tip of the arrow) confirms distal syndesmotic ligamentous injury.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Karen Maughan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_42_21153=[""].join("\n");
var outline_f20_42_21153=null;
var title_f20_42_21154="Apical 4C echo MAC and TAC";
var content_f20_42_21154=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F86968&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F86968&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Apical four-chamber echocardiogram with mitral (MAC) and tricuspid (TAC)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 386px; height: 441px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Four-chamber echocardiographic image from a patient with end-stage renal disease. There is tricuspid annular calcification (TAC) and mitral annular calcification (MAC).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rosario V Freeman, MD, MS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_42_21154=[""].join("\n");
var outline_f20_42_21154=null;
var title_f20_42_21155="Patient information: Swelling (The Basics)";
var content_f20_42_21155=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15597\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/27/43440\">",
"         Putting on compression stockings",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/48/26368\">",
"          Heel-pocket-out method to put on compression stockings",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/43/16050\">",
"           Pitting edema",
"          </a>",
"          <li>",
"           <a class=\"graphic graphic_table\" href=\"UTD.htm?12/29/12764\">",
"            Tips for using compression stockings",
"           </a>",
"          </li>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?27/35/28212\">",
"         Patient information: Chronic kidney disease (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?24/25/24979\">",
"         Patient information: Cirrhosis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?1/3/1075\">",
"         Patient information: Deep vein thrombosis (blood clots in the legs) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?17/12/17601\">",
"         Patient information: Heart failure (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?13/5/13398\">",
"         Patient information: Chronic kidney disease (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?34/17/35091\">",
"         Patient information: Chronic venous disease (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?43/3/44084\">",
"         Patient information: Cirrhosis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?12/44/12998\">",
"         Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?31/53/32594\">",
"         Patient information: Edema (swelling) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/5/33877\">",
"         Patient information: Heart failure (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?38/61/39890\">",
"         Patient information: Low sodium diet (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/58/40867\">",
"         Patient information: Preeclampsia (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?13/12/13510\">",
"         Patient information: Premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Swelling (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/swelling-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H1670212818\">",
"      <span class=\"h1\">",
"       What is swelling?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Swelling happens when fluid collects in small spaces around tissues and organs inside the body. Another word for swelling is &ldquo;edema.&rdquo; Some common parts of the body where people can have swelling are the:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Lower legs or hands",
"       </li>",
"       <li>",
"        Belly",
"       </li>",
"       <li>",
"        Chest &ndash; Swelling can occur in the lungs or in the space around the lungs.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Swelling in the legs, hands, and belly can be uncomfortable and can be a symptom of a more serious condition. Swelling in the lungs can be life-threatening, because it is usually a symptom of a serious heart problem.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1670212825\">",
"      <span class=\"h1\">",
"       What are the symptoms of swelling?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Symptoms of swelling can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Puffiness of the skin, which can cause the skin to look stretched and shiny &ndash; This often occurs with swelling in the lower legs or lower back, and can be worse after people sit or stand for a long time (",
"        <a class=\"graphic graphic_picture graphicRef61706 \" href=\"UTD.htm?15/43/16050\">",
"         picture 1",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        Increase in belly size (with swelling of the belly)",
"       </li>",
"       <li>",
"        Trouble breathing (with swelling in the chest)",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1670212832\">",
"      <span class=\"h1\">",
"       What are the causes of swelling?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Different conditions can cause swelling. Some of these include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Problems with veins (blood vessels) in the legs &ndash; Normally, veins carry blood from the body back to the heart. But if valves in the veins do not work well, the veins cannot pump enough blood back to the heart. This can cause swelling in the lower legs.",
"       </li>",
"       <li>",
"        Blood clots &ndash; People who have a blood clot blocking a leg vein can have swelling in the feet or ankles.",
"       </li>",
"       <li>",
"        Pregnancy &ndash; Pregnant women can have swelling in the hands, feet, or face.",
"       </li>",
"       <li>",
"        Monthly periods &ndash; Women can have swelling in different parts of their body before they get their period.",
"       </li>",
"       <li>",
"        Medicines &ndash; Swelling can be a side effect of some medicines, such as medicines for diabetes, high blood pressure, or pain.",
"       </li>",
"       <li>",
"        Kidney problems &ndash; People who have certain kidney problems can have swelling in the lower legs or around the eyes.",
"       </li>",
"       <li>",
"        Heart failure &ndash; Heart failure is a type of heart problem in which the heart cannot pump normally. People with heart failure can have swelling in the legs, belly, or lungs.",
"       </li>",
"       <li>",
"        Liver problems &ndash; People who have certain liver problems can have swelling in the belly or lower legs.",
"       </li>",
"       <li>",
"        Travel &ndash; People who sit for a long time when traveling can have swelling in the lower legs.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1670212839\">",
"      <span class=\"h1\">",
"       When should I call my doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Call your doctor or nurse if you have new swelling:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        In one or both of your legs",
"       </li>",
"       <li>",
"        In your hands",
"       </li>",
"       <li>",
"        In your belly",
"       </li>",
"       <li>",
"        Around your eyes",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      You should also call your doctor or nurse if you travel and sit for a long time, and then have leg pain or swelling that does not go away after a few days.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1670212846\">",
"      <span class=\"h1\">",
"       How is swelling treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Doctors can treat swelling in different ways, depending on the cause. Treatment can include one or more of the following:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Treatment for the medical condition that is causing the swelling",
"       </li>",
"       <li>",
"        Diet changes to reduce the amount of salt in the food that you eat",
"       </li>",
"       <li>",
"        Medicines to help your body get rid of extra fluid",
"       </li>",
"       <li>",
"        Special socks called &ldquo;compression stockings&rdquo; &ndash; These fit tightly over the ankle and leg, and can reduce leg swelling. If your doctor or nurse recommends that you wear them, he or she will tell you which type to wear and how to put them on (",
"        <a class=\"graphic graphic_figure graphicRef81922 \" href=\"UTD.htm?42/27/43440\">",
"         figure 1",
"        </a>",
"        and",
"        <a class=\"graphic graphic_figure graphicRef53659 \" href=\"UTD.htm?25/48/26368\">",
"         figure 2",
"        </a>",
"        and",
"        <a class=\"graphic graphic_table graphicRef57705 \" href=\"UTD.htm?12/29/12764\">",
"         table 1",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        Raising the legs up &ndash; Some people can reduce swelling in the legs, ankles, and feet by raising their legs up 3 or 4 times a day for 30 minutes each time. The legs need to be raised above the level of the heart.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Not all types of swelling need treatment. For example, swelling that occurs during pregnancy or before monthly periods usually does not need treatment.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1670212853\">",
"      <span class=\"h1\">",
"       How can I help prevent leg swelling when I travel on long flights?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To help prevent leg swelling on flights that are longer than 6 to 8 hours, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Stand up and walk around every hour or two",
"       </li>",
"       <li>",
"        Not smoke before traveling",
"       </li>",
"       <li>",
"        Wear loose-fitting and comfortable clothes",
"       </li>",
"       <li>",
"        Ask if you can sit in the bulkhead or emergency exit row",
"       </li>",
"       <li>",
"        Point and flex your feet, and bend your knees from time to time",
"       </li>",
"       <li>",
"        Drink plenty of fluids, and avoid drinking alcohol",
"       </li>",
"       <li>",
"        Not take medicines such as sleeping pills that can prevent you from getting up and moving around",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1670212860\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/12/17601?source=see_link\">",
"       Patient information: Heart failure (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/25/24979?source=see_link\">",
"       Patient information: Cirrhosis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/3/1075?source=see_link\">",
"       Patient information: Deep vein thrombosis (blood clots in the legs) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/35/28212?source=see_link\">",
"       Patient information: Chronic kidney disease (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/53/32594?source=see_link\">",
"       Patient information: Edema (swelling) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?43/3/44084?source=see_link\">",
"       Patient information: Cirrhosis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33877?source=see_link\">",
"       Patient information: Heart failure (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/12/13510?source=see_link\">",
"       Patient information: Premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/17/35091?source=see_link\">",
"       Patient information: Chronic venous disease (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?12/44/12998?source=see_link\">",
"       Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/58/40867?source=see_link\">",
"       Patient information: Preeclampsia (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/5/13398?source=see_link\">",
"       Patient information: Chronic kidney disease (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/61/39890?source=see_link\">",
"       Patient information: Low sodium diet (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?20/42/21155?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15597 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-125.39.66.147-BCDCD7344F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_42_21155=[""].join("\n");
var outline_f20_42_21155=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1670212818\">",
"      What is swelling?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1670212825\">",
"      What are the symptoms of swelling?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1670212832\">",
"      What are the causes of swelling?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1670212839\">",
"      When should I call my doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1670212846\">",
"      How is swelling treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1670212853\">",
"      How can I help prevent leg swelling when I travel on long flights?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1670212860\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15597\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/27/43440\">",
"      Putting on compression stockings",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/48/26368\">",
"       Heel-pocket-out method to put on compression stockings",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/43/16050\">",
"        Pitting edema",
"       </a>",
"       <li>",
"        <a class=\"graphic graphic_table\" href=\"UTD.htm?12/29/12764\">",
"         Tips for using compression stockings",
"        </a>",
"       </li>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/5/13398?source=related_link\">",
"      Patient information: Chronic kidney disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/35/28212?source=related_link\">",
"      Patient information: Chronic kidney disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/17/35091?source=related_link\">",
"      Patient information: Chronic venous disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/3/44084?source=related_link\">",
"      Patient information: Cirrhosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/25/24979?source=related_link\">",
"      Patient information: Cirrhosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?12/44/12998?source=related_link\">",
"      Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/3/1075?source=related_link\">",
"      Patient information: Deep vein thrombosis (blood clots in the legs) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/53/32594?source=related_link\">",
"      Patient information: Edema (swelling) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33877?source=related_link\">",
"      Patient information: Heart failure (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/12/17601?source=related_link\">",
"      Patient information: Heart failure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/61/39890?source=related_link\">",
"      Patient information: Low sodium diet (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/58/40867?source=related_link\">",
"      Patient information: Preeclampsia (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/12/13510?source=related_link\">",
"      Patient information: Premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_42_21156="Patient information: Recovery after coronary artery bypass graft surgery (CABG) (The Basics)";
var content_f20_42_21156=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16429\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/10/8356\">",
"         Coronary heart disease",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/38/42598\">",
"          Foods with fiber",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/15/1268\">",
"           Heart attack symptoms",
"          </a>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?20/34/21027\">",
"         Patient information: Chest pain (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/10/27809\">",
"         Patient information: Coronary heart disease (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/35/11827\">",
"         Patient information: Diet and health (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?19/39/20083\">",
"         Patient information: Exercise (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?9/53/10068\">",
"         Patient information: Heart attack (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/58/34722\">",
"         Patient information: High blood pressure in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?10/48/11011\">",
"         Patient information: High cholesterol (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/27/21940\">",
"         Patient information: Medicines after a heart attack (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?17/46/18146\">",
"         Patient information: Quitting smoking (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?6/21/6483\">",
"         Patient information: Reducing the costs of medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?0/24/386\">",
"         Patient information: Sex problems in men (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/17/11538\">",
"         Patient information: Sex problems in women (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?15/49/16147\">",
"         Patient information: Treatment for type 2 diabetes (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?30/62/31717\">",
"         Patient information: Coronary artery bypass graft surgery (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/62/28642\">",
"         Patient information: Diet and health (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/16/40195\">",
"         Patient information: Heart attack (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/32/37380\">",
"         Patient information: High blood pressure treatment in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?6/4/6212\">",
"         Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?40/1/40980\">",
"         Patient information: Preventing complications in diabetes mellitus (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?19/13/19670\">",
"         Patient information: Quitting smoking (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?28/33/29205\">",
"         Patient information: Sexual problems in men (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?12/4/12357\">",
"         Patient information: Sexual problems in women (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Recovery after coronary artery bypass graft surgery (CABG) (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/recovery-after-coronary-artery-bypass-graft-surgery-cabg-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H12914309\">",
"      <span class=\"h1\">",
"       What happens after coronary artery bypass graft surgery?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After coronary artery bypass graft surgery, or &ldquo;CABG,&rdquo; your doctor will make a treatment plan with you. The goals of this plan are to:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Treat your coronary heart disease &mdash; Even after your CABG, some of the heart&rsquo;s blood vessels can still have areas that are too narrow (",
"        <a class=\"graphic graphic_figure graphicRef61785 \" href=\"UTD.htm?8/10/8356\">",
"         figure 1",
"        </a>",
"        ). Also, your heart muscle might have been damaged before your CABG. Your doctor&rsquo;s plan can help lower the chances that these problems will affect your life in the future.",
"       </li>",
"       <li>",
"        Help you feel better and have more energy",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12914316\">",
"      <span class=\"h1\">",
"       How do I take care of my wounds?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor or nurse will tell you how to take care of any wounds on your chest, legs, or arms. It&rsquo;s important to watch for signs of an infection, especially during the first 2 weeks after your surgery. Call your doctor or nurse right away if you have any of the following:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Fever higher than 100.4&deg;F (38&deg;C)",
"       </li>",
"       <li>",
"        New pain or pain that is worse in your chest or around your chest wound",
"       </li>",
"       <li>",
"        A very fast heartbeat",
"       </li>",
"       <li>",
"        A wound that is bleeding, draining pus, or has redness around it",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12914323\">",
"      <span class=\"h1\">",
"       Do I need to take medicines?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Most people need to take more than 1 heart medicine every day. Doctors can prescribe different types of heart medicines. (See",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/27/21940?source=see_link\">",
"       \"Patient information: Medicines after a heart attack (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/10/27809?source=see_link\">",
"       \"Patient information: Coronary heart disease (The Basics)\"",
"      </a>",
"      .) The medicines can help you live longer and prevent blockages in your blood vessels from getting worse. Some also help treat chest pain and other heart symptoms.",
"     </p>",
"     <p>",
"      If you have high blood pressure, high cholesterol, or diabetes (high blood sugar), your doctor will likely prescribe medicines to treat those conditions.",
"     </p>",
"     <p>",
"      It&rsquo;s important to take your medicines exactly the way your doctor says. Let your doctor or nurse know if you have any side effects or problems with the medicines. You should also let him or her know if you can&rsquo;t afford your medicines. There are often ways to solve these problems.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12914330\">",
"      <span class=\"h1\">",
"       What is cardiac rehab?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Cardiac rehab (short for &ldquo;cardiac rehabilitation&rdquo;) is a program that your doctor might recommend for you. At cardiac rehab, doctors, nurses, and other health professionals teach you how to keep your heart healthy. They will help you:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Exercise safely &mdash; Getting regular exercise can help keep your heart healthy. Your doctor or nurse will work with you to make an exercise program that is safe for you. He or she will tell you how often and how hard to exercise.",
"        <br/>",
"        <br/>",
"        Each time you exercise, make sure to warm up for 5 to 10 minutes first. Then you can do &ldquo;aerobic exercise&rdquo; for at least 20 minutes. Aerobic exercise raises your heart rate and includes activities such as walking, swimming, and jogging. After you work out, make sure to cool down for 5 to 10 minutes.",
"       </li>",
"       <li>",
"        Improve your diet &mdash; Eating the right foods can help keep your heart healthy. Fruits, vegetables, and foods with fiber can help prevent heart disease and strokes (",
"        <a class=\"graphic graphic_figure graphicRef79063 \" href=\"UTD.htm?41/38/42598\">",
"         figure 2",
"        </a>",
"        ). Try to avoid eating foods that can make heart disease worse. These include &ldquo;trans&rdquo; fats, which are found in many fast foods. &ldquo;Saturated&rdquo; fats, which are found in red meats and many cheeses, can also worsen heart disease.",
"       </li>",
"       <li>",
"        Lose weight, if you are overweight.",
"       </li>",
"       <li>",
"        Quit smoking, if you smoke &mdash; Stopping smoking can lower your chance of getting or dying from heart disease. To quit, you can try nicotine patches, gum, or nasal sprays. (Nicotine is the main drug in cigarettes.) You can also try a prescription medicine to help stop cigarette cravings.",
"       </li>",
"       <li>",
"        Cope with feeling sad or worried &mdash; Many people feel sad or worried after CABG. Your doctor or counselor can help you with these feelings and, if needed, treat your depression.",
"       </li>",
"       <li>",
"        Reduce the stress in your life &mdash; Stress can worsen heart disease.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12914337\">",
"      <span class=\"h1\">",
"       When can I have sex again?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Check with your doctor about when it is safe to start having sex again. If you had a heart attack, the timing will depend on your heart attack and if you still have symptoms.",
"     </p>",
"     <p>",
"      After CABG, some people are less interested in sex or do not enjoy sex as much. This can be a side effect of certain heart medicines. It can also happen if people are sad or worried about having a heart attack during sex. If you have problems with sex, let your doctor or nurse know. He or she might be able to treat it.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12914344\">",
"      <span class=\"h1\">",
"       When can I drive again?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Check with your doctor. He or she might not want you to drive again until your chest has healed from your surgery.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12914351\">",
"      <span class=\"h1\">",
"       Which symptoms should I watch for?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It&rsquo;s important to watch for chest pain or symptoms of a heart attack (",
"      <a class=\"graphic graphic_figure graphicRef52579 \" href=\"UTD.htm?1/15/1268\">",
"       figure 3",
"      </a>",
"      ). But it is uncommon for people to have a heart attack in the months after CABG.",
"     </p>",
"     <p>",
"      If you think you might be having a heart attack,",
"      <strong>",
"       call 9-1-1 right away",
"      </strong>",
"      . Do not try to get to the hospital on your own.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12914358\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/53/10068?source=see_link\">",
"       Patient information: Heart attack (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/27/21940?source=see_link\">",
"       Patient information: Medicines after a heart attack (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/34/21027?source=see_link\">",
"       Patient information: Chest pain (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/46/18146?source=see_link\">",
"       Patient information: Quitting smoking (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/39/20083?source=see_link\">",
"       Patient information: Exercise (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/35/11827?source=see_link\">",
"       Patient information: Diet and health (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/58/34722?source=see_link\">",
"       Patient information: High blood pressure in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?10/48/11011?source=see_link\">",
"       Patient information: High cholesterol (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?15/49/16147?source=see_link\">",
"       Patient information: Treatment for type 2 diabetes (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/24/386?source=see_link\">",
"       Patient information: Sex problems in men (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/17/11538?source=see_link\">",
"       Patient information: Sex problems in women (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=see_link\">",
"       Patient information: Reducing the costs of medicines (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/10/27809?source=see_link\">",
"       Patient information: Coronary heart disease (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/62/31717?source=see_link\">",
"       Patient information: Coronary artery bypass graft surgery (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?6/4/6212?source=see_link\">",
"       Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?27/62/28642?source=see_link\">",
"       Patient information: Diet and health (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=see_link\">",
"       Patient information: Quitting smoking (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?36/32/37380?source=see_link\">",
"       Patient information: High blood pressure treatment in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?40/1/40980?source=see_link\">",
"       Patient information: Preventing complications in diabetes mellitus (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/33/29205?source=see_link\">",
"       Patient information: Sexual problems in men (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?12/4/12357?source=see_link\">",
"       Patient information: Sexual problems in women (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/16/40195?source=see_link\">",
"       Patient information: Heart attack (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?20/42/21156?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16429 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-66B715A8D5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_42_21156=[""].join("\n");
var outline_f20_42_21156=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12914309\">",
"      What happens after coronary artery bypass graft surgery?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12914316\">",
"      How do I take care of my wounds?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12914323\">",
"      Do I need to take medicines?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12914330\">",
"      What is cardiac rehab?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12914337\">",
"      When can I have sex again?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12914344\">",
"      When can I drive again?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12914351\">",
"      Which symptoms should I watch for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12914358\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16429\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/10/8356\">",
"      Coronary heart disease",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/38/42598\">",
"       Foods with fiber",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/15/1268\">",
"        Heart attack symptoms",
"       </a>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/34/21027?source=related_link\">",
"      Patient information: Chest pain (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/62/31717?source=related_link\">",
"      Patient information: Coronary artery bypass graft surgery (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/10/27809?source=related_link\">",
"      Patient information: Coronary heart disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/62/28642?source=related_link\">",
"      Patient information: Diet and health (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/35/11827?source=related_link\">",
"      Patient information: Diet and health (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/39/20083?source=related_link\">",
"      Patient information: Exercise (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/16/40195?source=related_link\">",
"      Patient information: Heart attack (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/53/10068?source=related_link\">",
"      Patient information: Heart attack (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/58/34722?source=related_link\">",
"      Patient information: High blood pressure in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/32/37380?source=related_link\">",
"      Patient information: High blood pressure treatment in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/48/11011?source=related_link\">",
"      Patient information: High cholesterol (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/4/6212?source=related_link\">",
"      Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/27/21940?source=related_link\">",
"      Patient information: Medicines after a heart attack (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/1/40980?source=related_link\">",
"      Patient information: Preventing complications in diabetes mellitus (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=related_link\">",
"      Patient information: Quitting smoking (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/46/18146?source=related_link\">",
"      Patient information: Quitting smoking (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=related_link\">",
"      Patient information: Reducing the costs of medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/24/386?source=related_link\">",
"      Patient information: Sex problems in men (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/17/11538?source=related_link\">",
"      Patient information: Sex problems in women (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/33/29205?source=related_link\">",
"      Patient information: Sexual problems in men (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?12/4/12357?source=related_link\">",
"      Patient information: Sexual problems in women (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?15/49/16147?source=related_link\">",
"      Patient information: Treatment for type 2 diabetes (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_42_21157="Patella fractures";
var content_f20_42_21157=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Patella fractures",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/42/21157/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/42/21157/contributors\">",
"     James G Blount, MD, CAQSM",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/42/21157/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/42/21157/contributors\">",
"     Patrice Eiff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/42/21157/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/42/21157/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/42/21157/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patella is the largest sesamoid bone and serves several important functions. It improves the mechanics of knee extension, protects the knee joint from direct trauma, and assists in providing nourishment for the articular cartilage of the distal femur [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21157/abstract/1\">",
"     1",
"    </a>",
"    ]. Patella fractures account for approximately 1 percent of all skeletal injuries in both adults and children.",
"   </p>",
"   <p>",
"    This topic will review fractures of the patella. Other injuries of the knee and lower extremity are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6618?source=see_link\">",
"     \"Evaluation of the active adult patient with knee pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/52/5957?source=see_link\">",
"     \"Proximal tibial fractures in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RELEVANT ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patella is triangular with the apex directed distally. The superior pole of the patella serves as the site for the insertion of the quadriceps tendon, which is the confluence of the four individual quadriceps muscle tendons (rectus femoris, vastus medialis, vastus intermedius, and vastus lateralis). The quadriceps tendon envelopes the patella and becomes the patella tendon distally, inserting on the tibial tuberosity. Forces exerted by the quadriceps muscles on the patella (eg, when landing on one's feet after a fall from a moderate height) can lead to indirect fracture and proximal retraction of the superior fracture piece, if there is complete disruption of bone or tendon.",
"   </p>",
"   <p>",
"    The medial patellar retinaculum is an extension of the vastus medialis tendon that attaches to the superomedial border of the patella and distally to the medial condyle of the tibia. The lateral patellar retinaculum is an extension of the vastus lateralis and attaches to the superolateral border of the patella and distally to the lateral condyle of the tibia. If the medial and lateral retinacula are intact following a patella fracture, the patient may retain the ability to actively extend the knee.",
"   </p>",
"   <p>",
"    The anastomoses of the superior, middle, and inferior geniculate arteries serve as the primary blood supply to the patella. Branches of these arteries enter the bone through the central patella and distal pole. Fractures through the mid-patella can thus compromise blood supply to the superior pole and increase the risk for avascular necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21157/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Bipartite patella",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patella develops with a single center of ossification 80 percent of the time. In the remaining 20 percent, two or three separate centers of ossification may exist. The patella develops into two separate pieces (ie, bipartite patella) when one of these ossification centers fails to fuse with the main patella. The incidence of bipartite patella is reported to range from 0.2 to 6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21157/abstract/2\">",
"     2",
"    </a>",
"    ]. The incidence of unilateral bipartite patella is unclear. Some claim it to be a rare phenomenon, while others report the incidence to approach 60 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21157/abstract/2\">",
"     2",
"    </a>",
"    ]. It is more common in males than females [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21157/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bipartite patella can be differentiated from acute patella fractures by radiographic appearance and location. Both pieces of a bipartite patella have smooth, well-corticated borders, and there is minimal separation between them. Furthermore, secondary ossification centers appear in specific locations. The Saupe classification of secondary ossification centers identifies three types in ascending order of frequency (",
"    <a class=\"graphic graphic_figure graphicRef68483 \" href=\"UTD.htm?8/22/8559\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef50267 \" href=\"UTD.htm?13/33/13855\">",
"     image 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Type 1 &ndash; Inferior pole (5 percent)",
"     </li>",
"     <li>",
"      Type 2 &ndash; Lateral or vertical (20 percent)",
"     </li>",
"     <li>",
"      Type 3 &ndash; Superolateral (75 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MECHANISM OF INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most fractures of the patella result from direct forces, such as a fall onto a flexed knee or striking the dashboard during an automobile accident. The clinician must carefully assess the femur, hip, and pelvis for injury if the patella fracture results from high-energy blunt trauma (eg, motor vehicle accident).",
"   </p>",
"   <p>",
"    Fractures can also result from an indirect force applied to the patella through sudden, forceful contraction of the quadriceps, such as landing on one's feet after jumping from a moderate height or coming to a sudden stop from a full sprint.",
"   </p>",
"   <p>",
"    Patella fractures are classified as displaced if there is greater than 2 mm of articular step-off or 3 mm of separation of the fracture fragments (ie, diastasis) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef59502 \" href=\"UTD.htm?2/62/3055\">",
"     image 2",
"    </a>",
"    ). Displaced fractures are referred for treatment. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Indications for orthopedic referral'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The mechanism of injury determines the fracture pattern. Direct, blunt trauma often causes comminuted, stellate fractures. These are more frequent in the elderly given their weakened bone and increased propensity to fall.",
"   </p>",
"   <p>",
"    Indirect trauma most commonly causes a transverse fracture, but it can also lead to lower pole or upper pole avulsion fractures. Transverse fractures usually involve the central or distal third of the patella, and there is often associated disruption of the medial and lateral retinacula. Patients with these fractures tend to be younger. Diastasis often results when contraction of the quadriceps pulls the superior fracture fragment proximally.",
"   </p>",
"   <p>",
"    Vertical fractures are much less common than either transverse or stellate fractures and can be produced by both indirect and direct forces. Osteochondral and chondral injuries can be caused by direct trauma and, in younger adults, can result from patella subluxation or dislocation. Stress fractures are uncommon but can be seen in athletes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION AND EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patella fracture should be considered when a patient presents with an acutely swollen knee and patella pain following direct or indirect trauma. It is most important that the clinician carefully assess the function of the extensor mechanism and look for any open fracture.",
"   </p>",
"   <p>",
"    Examination typically reveals a joint effusion and focal tenderness of the patella. The patient may not be able to extend the knee against gravity, and a gap in the extensor mechanism may be palpable. A hemarthrosis is noted if the joint is aspirated to relieve the pain from a tense effusion.",
"   </p>",
"   <p>",
"    Examination of the knee extensor mechanism is important because disruption requires surgical repair. Intraarticular injection of analgesic may be necessary to determine whether inability to extend the knee is due to pain rather than disruption of the extensor mechanism. A randomized study of analgesia from intraarticular injection following arthroscopic knee surgery found",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/41/10901?source=see_link\">",
"     neostigmine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    provided greater pain relief than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    , but it is not clear whether using one analgesic versus another improves knee examination in the acute setting [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21157/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The knee extensor mechanism can be assessed by having the patient bend the knee, either by allowing the injured leg to dangle over the side of the examination table or by placing towels under the injured knee, and then having the patient extend the knee against gravity. This maneuver should be done gently after pain is relieved.",
"   </p>",
"   <p>",
"    Overlying lacerations and abrasions are often present when the mechanism of injury involves a fall onto the knee. The possibility of intraarticular communication (ie, open fracture) must be excluded in this circumstance. This can be done by injecting saline with a small amount of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/7/1143?source=see_link\">",
"     methylene blue",
"    </a>",
"    dye into the joint away from the laceration or puncture wound in question and looking for extravasation from the wound.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     RADIOGRAPHIC FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A patella fracture is diagnosed by x-ray. Standard radiographic evaluation includes anteroposterior (AP), lateral, and sunrise views (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef65002 \" href=\"UTD.htm?9/1/9247\">",
"     image 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef75306 \" href=\"UTD.htm?39/11/40126\">",
"     image 4",
"    </a>",
"    ). The lateral view is generally most helpful for assessing displacement (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef81585 \" href=\"UTD.htm?36/61/37854\">",
"     image 5",
"    </a>",
"    ). A tangential view can be helpful in identifying osteochondral fragments and in assessing vertical fractures (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef82192 \" href=\"UTD.htm?1/10/1199\">",
"     image 6",
"    </a>",
"    ). Contralateral views can confirm bipartite patella. It is important to remember, however, that the incidence of bilateral bipartite patella may be as low as 40 percent (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef50267 \" href=\"UTD.htm?13/33/13855\">",
"     image 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Bipartite patella'",
"    </a>",
"    above.) Magnetic resonance imaging can help assess injury to the cartilage and can identify fractures not visible on plain x-ray. Bone scans can exclude the rare stress fracture in an athlete [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21157/abstract/5\">",
"     5",
"    </a>",
"    ]. In skilled hands, ultrasound can be used to diagnose some patella fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21157/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR ORTHOPEDIC REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Referral for operative repair is recommended in the following circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fractures with greater than 2 mm of articular step-off (ie, displacement) (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef59502 \" href=\"UTD.htm?2/62/3055\">",
"       image 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Fractures with greater than 3 mm of fragment separation (ie, diastasis) (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef59502 \" href=\"UTD.htm?2/62/3055\">",
"       image 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Comminuted fractures with displacement of the articular surface",
"     </li>",
"     <li>",
"      Disruption of the extensor mechanism",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients who are debilitated, poor surgical candidates for other reasons, or who have poor bone quality are often managed nonoperatively.",
"   </p>",
"   <p>",
"    The goal of operative repair is rigid bone fixation that allows for early joint motion and rehabilitation, restoration of articular congruity to minimize the risk of degenerative arthritis, and ultimately restoration of function. The multiple techniques for internal fixation of transverse fractures are a topic of considerable debate among surgeons.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     INITIAL TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Operative management is recommended for displaced or complex fractures in patients able to tolerate both the procedure and postoperative rehabilitation (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Indications for orthopedic referral'",
"    </a>",
"    above). Nondisplaced patella fractures with an intact extensor mechanism that do not meet operative criteria can be treated nonsurgically.",
"   </p>",
"   <p>",
"    Acutely, nonsurgical patients should be placed in a knee immobilizer or splint put in extension. Patients are not to bear weight on the injured leg until a cast is placed. Compression, ice, and elevation of the leg are important to control swelling and related pain.",
"   </p>",
"   <p>",
"    Patients should perform strength exercises, including isometric contraction of the quadriceps and straight leg raises (",
"    <a class=\"graphic graphic_picture graphicRef55455 graphicRef64621 \" href=\"UTD.htm?30/0/30727\">",
"     picture 1A-B",
"    </a>",
"    ), while their knee is immobilized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     FOLLOW-UP CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Definitive treatment consists of immobilization with a cylinder cast from the groin to the ankle (ending just proximal to the malleoli), with the knee in extension (not hyperextension), for four to six weeks. The cast is generally placed five to seven days following injury to allow swelling to subside. For the elderly and very compliant patients, continued immobilization with a knee immobilizer in lieu of a cast may be appropriate.",
"   </p>",
"   <p>",
"    While there is some debate as to whether to allow weight-bearing once the cast is placed, many feel that weight-bearing as tolerated and quadriceps exercises are important to limit bone loss and muscular atrophy.",
"   </p>",
"   <p>",
"    Follow-up radiographs should be taken two weeks after the injury, to ensure the fracture remains nondisplaced, and again four to six weeks after the injury, to look for callus formation. Surgical referral is made if displacement occurs. The cast is removed when callus is seen on x-ray. Complete healing requires 8 to 10 weeks.",
"   </p>",
"   <p>",
"    After cast removal, patients begin rehabilitation with knee range of motion exercises. Gradually, strengthening exercises are added to the regimen, usually as part of formal physical therapy. Gradual return to noncontact sports is allowed as tolerated. Healing typically requires 8 to 10 weeks. It is reasonable to restrict patients from participation in contact sports during that period.",
"   </p>",
"   <p>",
"    Nondisplaced marginal vertical fractures do not require immobilization. They are treated with activity modification for four to six weeks and progressive range of motion and strengthening exercises.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications after nonoperative treatment of nondisplaced fractures include decreased knee range of motion (generally loss of terminal extension), weakness due to prolonged immobilization, nonunion, and patellofemoral joint pain. There is increased risk of the development of osteoarthritis. Loss of terminal extension or persistent extension lag is not uncommon, but it usually does not compromise function or ability to return to sport. Nonunion is rare. Degenerative arthritis develops after severely comminuted fractures. Patellofemoral pain is treated in standard fashion: icing, stretching of the hamstrings and iliotibial band, and quadriceps",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    gluteal strengthening as indicated by examination.",
"   </p>",
"   <p>",
"    Complications of operative treatment include infection, failure of hardware (eg, wires breaking), decreased range of motion, nonunion, and osteonecrosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     RETURN TO WORK AND SPORTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Job requirements and symptoms determine the speed with which patients can return to work. Patients with sedentary jobs may be able to return to work after several days of rest, ice, and elevation if their symptoms are manageable.",
"   </p>",
"   <p>",
"    Patients with active jobs requiring knee flexion (eg, squatting, climbing stairs) should rest from work until knee immobilization is no longer required for treatment and they can perform work-related tasks without unreasonable discomfort. This generally requires six to eight weeks.",
"   </p>",
"   <p>",
"    Athletes should perform rehabilitation exercises while their knee is immobilized. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Follow-up care'",
"    </a>",
"    above.) Once immobilization is no longer needed, they may begin activities that require minimal knee flexion, such as walking. Activity intensity and duration should progress gradually under the guidance of a physical therapist or athletic trainer. Those activities which place greatest stress on the quadriceps mechanism, such as vigorous jumping and abrupt changes in direction, are added last.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/36/7747?source=see_link\">",
"       \"Patient information: Knee pain (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?24/4/24642?source=see_link\">",
"       \"Patient information: Knee pain (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patella fractures result from either blunt trauma or indirect force applied through a contracting quadriceps. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Mechanism of injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Assessment of extensor mechanism integrity (the ability to extend the leg against gravity) and for the presence of an open fracture are of utmost importance. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical presentation and examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Standard radiographic evaluation includes anteroposterior (AP), lateral, and sunrise views. The lateral view is generally most helpful for assessing displacement. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Radiographic findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Orthopedic referral for operative management is indicated for: fractures with greater than 2 mm of articular step-off; fractures with greater than 3 mm of fragment separation; comminuted fractures with displacement of the articular surface; and disruption of the extensor mechanism. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Indications for orthopedic referral'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Initial treatment includes immobilization of the knee in extension with a knee immobilizer. Definitive treatment consists of continued immobilization with a cylinder cast from the groin to the ankle (ending just proximal to the malleoli), with the knee in extension, for four to six weeks. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Initial treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Follow-up care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Job requirements and symptoms determine the speed with which patients can return to work. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Return to work and sports'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Harris, RM. Fracture of the patella. In: Rockwood and Green's Fractures in Adults, Bucholz, RW, Heckman, JD (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2002. p.1775.",
"    </li>",
"    <li>",
"     Sponseller, PD, Stanitski, CL. Fractures and dislocation. In: Rockwood and Wilkin's Fractures in Children, Beaty, BH, Kasser, JK (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2001. p.981.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21157/abstract/3\">",
"      Bostr&ouml;m A. Fracture of the patella. A study of 422 patellar fractures. Acta Orthop Scand Suppl 1972; 143:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21157/abstract/4\">",
"      Alagol A, Calpur OU, Usar PS, et al. Intraarticular analgesia after arthroscopic knee surgery: comparison of neostigmine, clonidine, tenoxicam, morphine and bupivacaine. Knee Surg Sports Traumatol Arthrosc 2005; 13:658.",
"     </a>",
"    </li>",
"    <li>",
"     DeLee, J, Drez, D. Patellar fractures in the adult. In: Orthopaedic Sports Medicine: Principle and Practice, 2nd, WB Saunders, Philadelphia 2003. p.1760.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21157/abstract/6\">",
"      Wilkerson RG, Stone MB. Ultrasound identification of patella fracture. Wilderness Environ Med 2009; 20:92.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 216 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-5849588C53-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_42_21157=[""].join("\n");
var outline_f20_42_21157=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RELEVANT ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Bipartite patella",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MECHANISM OF INJURY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL PRESENTATION AND EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      RADIOGRAPHIC FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      INDICATIONS FOR ORTHOPEDIC REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      INITIAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      FOLLOW-UP CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      RETURN TO WORK AND SPORTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/216\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/216|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?13/33/13855\" title=\"diagnostic image 1\">",
"      Type III bipartite patella",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/62/3055\" title=\"diagnostic image 2\">",
"      Lateral view displaced transverse patella fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?9/1/9247\" title=\"diagnostic image 3\">",
"      AP view transverse patella fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?39/11/40126\" title=\"diagnostic image 4\">",
"      Sunrise view patella",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?36/61/37854\" title=\"diagnostic image 5\">",
"      Lateral view of minimally displaced transverse patella fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?1/10/1199\" title=\"diagnostic image 6\">",
"      Transverse patella fracture oblique view",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/216|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/22/8559\" title=\"figure 1\">",
"      Ossification centers patella",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/216|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/13/30929\" title=\"picture 1A\">",
"      Starting position for straight leg raise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/15/9459\" title=\"picture 1B\">",
"      Straight leg raise patella fracture",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6618?source=related_link\">",
"      Evaluation of the active adult patient with knee pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/4/24642?source=related_link\">",
"      Patient information: Knee pain (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/36/7747?source=related_link\">",
"      Patient information: Knee pain (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/52/5957?source=related_link\">",
"      Proximal tibial fractures in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_42_21158="Nitrazepam: Drug information";
var content_f20_42_21158=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Nitrazepam: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?22/54/23396?source=see_link\">",
"    see \"Nitrazepam: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F2934283\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Nitrazepam&reg;;",
"     </li>",
"     <li>",
"      Mogadon;",
"     </li>",
"     <li>",
"      Nitrazadon&reg;;",
"     </li>",
"     <li>",
"      Sandoz-Nitrazepam",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F3950304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Benzodiazepine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F3950332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Insomnia:",
"     </b>",
"     Oral: 5-10 mg at bedtime; treatment should not exceed 7-10 consecutive days; use for more than 2-3 consecutive weeks requires complete re-evaluation of patient",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F3950331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Myoclonic seizures:",
"     </b>",
"     Children &le;30 kg: Oral: Usual dosage: 0.3-1 mg/kg/day in 3 divided doses;",
"     <b>",
"      Note:",
"     </b>",
"     Therapy should be initiated below the usual dosage range and titrated carefully based on response. If inadequate response to usual dosage, may gradually increase dose further. Manufacturer labeling does not specify a maximum dosage.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3950333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Insomnia: Elderly or debilitated patients: Oral: Initial: 2.5 mg at bedtime; may increase dose to5 mg if tolerated (maximum dose: 5 mg/day)",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F5950133\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Apo-Nitrazepam&reg;, Mogadon, Nitrazadon, Nitrazepam (Pro-Doc), Sandoz-Nitrazepam: 5 mg, 10  mg",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11234093\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not available in U.S.",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F3950277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CDSA IV",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F3950334\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tablets may be swallowed whole, crushed, or dissolved in liquid. For insomnia, administer at bedtime. For myoclonic seizures, administer in 3 equally divided doses, or if doses are not divided equally, give larger dose at bedtime.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F245358\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Short-term management of insomnia; treatment of myoclonic seizures",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F3950311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Hypotension, palpitation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation, aggressiveness, amnesia, ataxia, confusion, delusions, depression, disorientation, dizziness, excitement, fatigue, hallucination, hangover, headache, hyperactivity,  irritability, lethargy, lightheadedness, nervousness, nightmares, psychoses, rage, restlessness, sedation, staggering",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Cutaneous reactions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Changes in libido",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, diarrhea, excessive salivation, heartburn, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Granulocytopenia, leukopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hepatic function tests abnormal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Delirium tremens, falling, muscle spasticity increased, muscle weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Aspiration, bronchial hypersecretion, dyspnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis/anaphylactoid reactions (angioedema, dyspnea, throat closing, nausea/vomiting)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F245361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to nitrazepam or any component of the formulation (cross sensitivity with other benzodiazepines may exist); myasthenia gravis; severe respiratory insufficiency (eg, significant sleep apnea syndrome); severe hepatic insufficiency; use as hypnotic in children",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F245350\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylaxis/anaphylactoid reactions: Have been reported with use; patients who develop angioedema should not be rechallenged with nitrazepam.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anterograde amnesia: May rarely induce anterograde amnesia (particularly in the elderly); caution patients to ensure they have uninterrupted sleep of 7-8 hours after ingestion of dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aspiration pneumonia: Bronchial hypersecretion and excessive salivation/drooling leading to aspiration pneumonia in young and elderly patients may occur rarely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Paradoxical reactions: Paradoxical reactions, including hyperactive or aggressive behavior, have been reported with benzodiazepines, particularly in adolescent/pediatric or psychiatric patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sleep-related activities: An increased risk for hazardous sleep-related activities such as sleep-driving; cooking and eating food, and making phone calls while asleep have also been noted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Depression: Use caution in patients with depression, particularly if suicidal risk may be present.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug abuse: Use with caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists. Tolerance, psychological and physical dependence may occur with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment (contraindicated in severe hepatic impairment).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with respiratory  disease (contraindicated in severe respiratory insufficiency).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depressants/psychoactive medications: Use with caution in patients receiving other CNS depressants or psychoactive medication; effects with other sedative drugs or ethanol may be potentiated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Debilitated patients: Use with caution in debilitated patients",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; benzodiazepines have been associated with falls and traumatic injury.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Associated with sudden death in children &lt;5 years of age being treated for seizure disorders. Use should be restricted to children unresponsive to other antiepileptic agents. Safety and efficacy for use as a hypnotic not established in children &lt;18 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Does not have analgesic, antidepressant, or antipsychotic properties.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypnotic: Appropriate use: Should be used only after evaluation of potential causes of sleep disturbance. Failure of sleep disturbance to resolve after 7-10 days may indicate psychiatric or medical illness. A worsening of insomnia or the emergence of new abnormalities of thought or behavior may represent unrecognized psychiatric or medical illness and requires immediate and careful evaluation. Prescribed quantities should typically be for short term (7-10 days) and not exceed a 1-month supply.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal: Rebound or withdrawal symptoms may occur following abrupt discontinuation or large decreases in dose. Use caution when reducing dose or withdrawing therapy; decrease slowly and monitor for withdrawal symptoms. Flumazenil may cause withdrawal in patients receiving long-term benzodiazepine therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F245353\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of Benzodiazepines (metabolized by oxidation). Management: The following combinations are specifically contraindicated: itraconazole with alprazolam, estazolam, oral midazolam, or triazolam; ketoconazole with alprazolam, estazolam, or triazolam.  Consider initial dose reductions of other benzodiazepines.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Benzodiazepines may enhance the adverse/toxic effect of CloZAPine.  Management: Consider decreasing the dose of (or possibly discontinuing) benzodiazepines prior to initiating clozapine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): May increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cosyntropin: May enhance the hepatotoxic effect of Nitrazepam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: May increase the serum concentration of Benzodiazepines (metabolized by oxidation). Specifically, the active metabolite aprepitant is likely responsible for this effect.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Benzodiazepines may increase the serum concentration of Fosphenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OLANZapine: May enhance the adverse/toxic effect of Benzodiazepines. Management: Avoid concomitant use of parenteral benzodiazepines and IM olanzapine due to risks of additive adverse events (e.g., cardiorespiratory depression). Olanzapine prescribing information provides no specific recommendations regarding oral administration.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Benzodiazepines may increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Lansoprazole; Pantoprazole; RABEprazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Citalopram; Escitalopram; PARoxetine; Sertraline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: Benzodiazepines may enhance the CNS depressant effect of Sodium Oxybate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May increase the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: May diminish the therapeutic effect of Benzodiazepines.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the therapeutic effect of Antianxiety Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F3950318\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethanol: Avoid ethanol (may increase CNS depression).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: Avoid valerian, kava kava,  St John&rsquo;s wort, gotu kola (may increase CNS depression).",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3950305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use during pregnancy is not recommended. Nitrazepam crosses the human placenta. Teratogenic effects have been observed with some benzodiazepines; however, additional studies are needed. The incidence of premature birth and low birth weights may be increased following maternal use of benzodiazepines; hypoglycemia and respiratory problems in the neonate may occur following exposure late in pregnancy. Neonatal withdrawal symptoms may occur within days to weeks after birth and &ldquo;floppy infant syndrome&rdquo; (which also includes withdrawal symptoms) have been reported with some benzodiazepines.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F3950307\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F3950308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Drowsiness, lethargy, or weight loss in nursing infants have been observed in case reports following maternal use of some benzodiazepines.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F3950336\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Respiratory and cardiovascular status",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F245357\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Steady state levels after 4 days: 40 ng/mL",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F2869334\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Alodorm (AU);",
"     </li>",
"     <li>",
"      Apodorm (NO, SE);",
"     </li>",
"     <li>",
"      Arem (ZA);",
"     </li>",
"     <li>",
"      Dumolid (ID);",
"     </li>",
"     <li>",
"      Eunoctin (HN);",
"     </li>",
"     <li>",
"      Hipnax (PT);",
"     </li>",
"     <li>",
"      Hypnotex (IN);",
"     </li>",
"     <li>",
"      Imeson (DE);",
"     </li>",
"     <li>",
"      Insomin (FI);",
"     </li>",
"     <li>",
"      Mogadon (AT, AU, BE, CH, DK, FR, HK, IT, MY, NL, NO, PK, SE, SG, TH);",
"     </li>",
"     <li>",
"      Mozepam (PH);",
"     </li>",
"     <li>",
"      Nitavan (IN);",
"     </li>",
"     <li>",
"      Nitrados (NZ, SG);",
"     </li>",
"     <li>",
"      Nitrapan (BR);",
"     </li>",
"     <li>",
"      Nitravet (IN);",
"     </li>",
"     <li>",
"      Nitrazepam (PL);",
"     </li>",
"     <li>",
"      Nitrazepol (BR);",
"     </li>",
"     <li>",
"      Nitrom (TW);",
"     </li>",
"     <li>",
"      Novanox (DE);",
"     </li>",
"     <li>",
"      Numbon (IL);",
"     </li>",
"     <li>",
"      Onirema (VE);",
"     </li>",
"     <li>",
"      Ormodon (ZA);",
"     </li>",
"     <li>",
"      Paxadorm (ZA);",
"     </li>",
"     <li>",
"      Radedorm (BG, EE);",
"     </li>",
"     <li>",
"      Rohypnol (PL);",
"     </li>",
"     <li>",
"      Sleepin (TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F245349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds to stereospecific benzodiazepine receptors on the postsynaptic GABA neuron at several sites within the CNS, including the limbic system, reticular formation. Enhancement of the inhibitory effect of GABA on neuronal excitability results by increased neuronal membrane permeability to chloride ions. This shift in chloride ions results in hyperpolarization (a less excitable state) and stabilization.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F245360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 20-50 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 2.4 L/kg, Elderly: 4.8 L/kg; also distributes into CSF, saliva",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 87%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic: Nitroreduction, acetylation; no active metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: ~80%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 30 hours, Elderly/ill patients: 40 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: ~3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine  (65% to 70%, ~1% as unchanged drug); feces (14% to 20%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/42/21158/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bergman U, Rosa FW, Baum C, et al, \"Effects of Exposure to Benzodiazepine During Fetal Life,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 1992, 340(8821):694-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/42/21158/abstract-text/1355799/pubmed\" id=\"1355799\" target=\"_blank\">",
"        1355799",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Iqbal MM, Sobhan T, Ryals T, et al, \"Effects of Commonly Used Benzodiazepines on the Fetus, the Neonate, and the Nursing Infant,\"",
"      <i>",
"       Psychiatr Serv",
"      </i>",
"      , 2002, 53(1):39-49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/42/21158/abstract-text/11773648/pubmed\" id=\"11773648\" target=\"_blank\">",
"        11773648",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Murphy JV, Sawasky F, Marquardt KM, et al, &ldquo;Deaths in Young Children Receiving Nitrazepam,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1987, 111(1):145-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/42/21158/abstract-text/3598778/pubmed\" id=\"3598778\" target=\"_blank\">",
"        3598778",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rintahaka PJ, Nakagawa JA, Shewmon DA, et al, &ldquo;Incidence of Death in Patients with Intractable Epilepsy During Nitrazepam Treatment,&rdquo;",
"      <i>",
"       Epilepsia",
"      </i>",
"      , 1999, 40(4): 492-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/42/21158/abstract-text/10219277/pubmed\" id=\"10219277\" target=\"_blank\">",
"        10219277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wikner BN, Stiller CO, Bergman U, et al, \"Use of Benzodiazepines and Benzodiazepine Receptor Agonists During Pregnancy: Neonatal Outcome and Congenital Malformations,\"",
"      <i>",
"       Pharmacoepidemiol Drug Saf",
"      </i>",
"      , 2007, 16(11):1203-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/42/21158/abstract-text/17894421/pubmed\" id=\"17894421\" target=\"_blank\">",
"        17894421",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10165 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-27.109.116.13-FFFC22E1CE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_42_21158=[""].join("\n");
var outline_f20_42_21158=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2934283\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3950304\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3950332\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3950331\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3950333\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5950133\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11234093\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3950277\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3950334\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F245358\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3950311\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F245361\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F245350\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299765\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F245353\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3950318\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3950305\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3950307\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3950308\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3950336\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F245357\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2869334\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F245349\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F245360\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10165\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10165|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?22/54/23396?source=related_link\">",
"      Nitrazepam: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_42_21159="Chronic progressive external ophthalmoplegia";
var content_f20_42_21159=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F76051&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F76051&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 604px\">",
"   <div class=\"ttl\">",
"    Chronic progressive external ophthalmoplegia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 584px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This patient has profound ptosis and ophthalmoplegia in all directions of gaze.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael S Lee, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_42_21159=[""].join("\n");
var outline_f20_42_21159=null;
var title_f20_42_21160="ECG third degree or complete AV block";
var content_f20_42_21160=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F72863&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F72863&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1117px;\">",
"  <div class=\"figure\" style=\"width: 547px\">",
"   <div class=\"ttl\">",
"    Single-lead electrocardiogram (ECG) showing sinus rhythm with third degree (complete) AV block",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 527px; height: 141px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sinus rhythm with third degree (complete) heart block. There is independent atrial (as shown by the P waves) and ventricular activity, with respective rates of 83 and 43 beats per minute. The wide QRS complexes may represent a junctional escape rhythm with underlying bundle branch block or an idioventricular pacemaker.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ary Goldberger, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal rhythm strip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 165px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton F Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_42_21160=[""].join("\n");
var outline_f20_42_21160=null;
var title_f20_42_21161="Clinical manifestations and diagnosis of visceral leishmaniasis";
var content_f20_42_21161=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of visceral leishmaniasis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/42/21161/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/42/21161/contributors\">",
"     Caryn Bern, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/42/21161/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/42/21161/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/42/21161/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/42/21161/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/42/21161/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 10, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Visceral leishmaniasis (VL) is primarily caused by L. donovani and L. infantum (synonym L. chagasi) (",
"    <a class=\"graphic graphic_table graphicRef58861 \" href=\"UTD.htm?13/56/14221\">",
"     table 1",
"    </a>",
"    ). Rarely, visceral disease has been reported in patients infected with leishmanial species usually associated with cutaneous disease, in particular, L. mexicana and L. tropica [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. The major clinical manifestations caused by L. donovani and L. infantum are not generally distinguishable, and specialized techniques are needed to identify the species. However, treatment decisions for VL usually do not require species identification since they are based on disease severity, geographic origin, and the presence of HIV and other co-infections.",
"   </p>",
"   <p>",
"    Issues related to clinical manifestations and diagnosis of visceral leishmaniasis will be reviewed here. Issues related to treatment of VL are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43625?source=see_link\">",
"     \"Treatment of visceral leishmaniasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leishmania invade and replicate within host macrophages, evading innate and cell-mediated immune responses. Infection generally appears to persist after clinical cure of the primary infection [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Evasion and persistence are achieved through a combination of strategies including neutralization of complement components, preventing release of macrophage superoxide and nitric oxide, and suppressing induction of antigen-specific CD4+ T helper lymphocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Spontaneous recovery is rare, although some relatively mild, self-limited cases of VL have been reported in a cohort of Brazilian children [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Asymptomatic infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many leishmaniasis infections are asymptomatic, reflecting the ability of the host immune system to control the parasite [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/9\">",
"     9",
"    </a>",
"    ]. The ratio of asymptomatic infection to clinically manifest disease varies widely, from &gt;30:1 in Europe to 6:1 in Brazilian children and 4:1 in Bangladesh. This may reflect differences in parasite virulence, human genetic predisposition, nutritional status, and other factors [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/10-16\">",
"     10-16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subclinical infections can be detected early in their course with serologic testing. The later development of a protective cell-mediated immune response can be detected via leishmanin skin testing (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Diagnosis'",
"    </a>",
"    below). The majority of patients with subclinical infection harbor viable parasites lifelong and can develop reactivation disease if immunosuppression occurs, although there does not appear to be a role for primary prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/5,17\">",
"     5,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Visceral leishmaniasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important clinical manifestation of VL is the syndrome known as kala-azar (Hindi for \"black fever\"). The incubation period is usually two to six months but can range from a few weeks to several years. Onset of symptoms is usually insidious or subacute, with slow progression of malaise, fever, weight loss, and splenomegaly (with or without hepatomegaly) over a period of months [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/9\">",
"     9",
"    </a>",
"    ]. In rare cases, acute febrile illness can occur with rapidly progressive symptoms.",
"   </p>",
"   <p>",
"    Patients may complain of abdominal discomfort and fullness that may be localized to the left upper quadrant. The spleen is usually firm and minimally tender, but in some patients palpation is quite painful, presumably due to capsular pressure from rapid enlargement [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/18\">",
"     18",
"    </a>",
"    ]. Hepatomegaly is usually less marked than splenomegaly. Lymphadenopathy may be observed in East African VL but is rare outside this region.",
"   </p>",
"   <p>",
"    Since parasites replicate in the reticuloendothelial system, very high parasite loads accumulate in the spleen, liver, and bone marrow. Severe anemia can occur due to bone marrow suppression, hemolysis, and splenic sequestration. Advanced kala-azar is associated with marked cachexia, hypoalbuminemia, and edema. Late in the course of disease, hepatic dysfunction, jaundice, and ascites can occur. Thrombocytopenia and hepatic dysfunction contribute to hemorrhagic complications. Patients may have spontaneous bleeding from the gingiva, nasal mucosa or other sites. Rarely, chronic diarrhea and malabsorption can occur as a result of parasitic invasion of the intestine [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Kala-azar (\"black fever\") refers to darkening of the skin, which is a common symptom in South Asia but not elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/20\">",
"     20",
"    </a>",
"    ]. This appears to have been more common in classic descriptions of the disease from the early 20th century but has also been reported in more recent case series [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Immunosuppression increases risk for secondary bacterial infections. Among 30 Brazilian children with kala-azar, 60 percent developed bacterial infections (eg, cutaneous and oral mucosal infections, pneumonia, otitis media, gastrointestinal infections, and sepsis) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Pathophysiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Kala-azar during pregnancy can lead to spontaneous abortion or congenital leishmaniasis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Leishmaniasis is nearly always lethal without treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. Even with treatment, fatality rates can be 10 percent or higher. Jaundice, wasting, severe anemia, and HIV co-infection are associated with increased mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. The triad of HIV, VL, and tuberculosis is increasingly reported in India and Ethiopia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/29\">",
"     29",
"    </a>",
"    ]. Tuberculosis coinfection also increases VL mortality, even in the absence of HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'HIV-VL coinfection'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Viscerotropic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Viscerotropic leishmaniasis is a term used for a systemic illness similar to but substantially milder than kala-azar. The syndrome was described among eight US military veterans of the 1991 Gulf War and was attributed to L. tropica infection (a species which usually causes cutaneous disease) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Symptoms included fever, malaise, cough, intermittent diarrhea, abdominal pain, adenopathy and mild hepatosplenomegaly. Treatment with sodium stibogluconate was administered to six patients; the remaining two had spontaneous recovery without antileishmanial treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24542225\">",
"    <span class=\"h3\">",
"     Renal impairment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild renal impairment appears to occur in a significant proportion of adults and children with visceral leishmaniasis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/32-35\">",
"     32-35",
"    </a>",
"    ]. All of the published data come from areas where VL is due to L. infantum, but this may reflect the paucity of laboratory services in areas with L. donovani rather than a true clinical difference.",
"   </p>",
"   <p>",
"    One study of 49 adults in Brazil demonstrated abnormal urinalysis (proteinuria, hematuria,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    white blood cells) in 32 percent, creatinine in 16 percent, elevated blood urea nitrogen in 8 percent, elevated quantitative proteinuria in 57 percent, and creatinine clearance &lt;80",
"    <span class=\"nowrap\">",
"     mL/min/1.7",
"    </span>",
"    m",
"    <sup>",
"     3",
"    </sup>",
"    in 37 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/33\">",
"     33",
"    </a>",
"    ]. Of seven patients who underwent renal biopsy, all had interstitial nephritis and three also had glomerulonephritis (considered minimal in two cases). The renal injury was reversible with effective treatment of VL. Within one month of treatment, all patients had normal serum creatinine and blood urea nitrogen concentration; the glomerular filtration rate improved but remained mildly diminished in 32 percent of cases.",
"   </p>",
"   <p>",
"    Another study including 146 Brazilian children noted renal impairment in 45 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/34\">",
"     34",
"    </a>",
"    ]. The estimated glomerular filtration rate was reduced by 25, 50, and 100 percent in 67, 31, and 1 percent of cases, respectively. The risk of renal impairment was increased among younger children and those with secondary bacterial infection. Patients treated with amphotericin had a lower rate of renal impairment compared to those treated with meglumine antimoniate. No patients required dialysis.",
"   </p>",
"   <p>",
"    Renal injury in VL is generally attributed to immune-complex interstitial nephritis, but animal studies suggest that the etiology may also involve cellular inflammatory responses [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Based on these data, renal function should be monitored routinely in VL, but the only treatment needed in most cases is effective antileishmanial therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonspecific laboratory findings of VL include anemia, neutropenia, eosinopenia, and thrombocytopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/9\">",
"     9",
"    </a>",
"    ]. The anemia is normocytic and normochromic, unless iron deficiency is also present. The etiology of anemia is thought to be multifactorial, including bone marrow suppression, hemolysis, and hypersplenism [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/37\">",
"     37",
"    </a>",
"    ]. An elevated neutrophil count is uncharacteristic of VL and should prompt a search for secondary bacterial infection. Elevated liver enzymes and bilirubin are also seen. Hypergammaglobulinemia results from polyclonal B cell activation. Severe anemia and frank jaundice are associated with a poor prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/26,30,38\">",
"     26,30,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific laboratory testing is needed to establish the diagnosis of visceral leishmaniasis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/9\">",
"     9",
"    </a>",
"    ]. Definitive diagnosis requires the demonstration of parasite by smear or culture in tissue (usually bone marrow or spleen). The utility of less invasive diagnostic tools (such as demonstration of specific antibodies, antigens, or parasite DNA in peripheral blood specimens) depends on the clinical status of the patient, the geographic origin of the parasite, the methods employed, and laboratory experience [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical and laboratory consultation for VL diagnosis, including access to serological and molecular testing, culture medium, and slide review, are available by contacting the CDC Parasitic Diseases Public Inquiries line (404-718-4745; email",
"    <a class=\"external\" href=\"mailto:parasites@cdc.gov\">",
"     parasites@cdc.gov",
"    </a>",
"    ), CDC Drug Service (770-488-7775), or for emergencies outside of business hours, CDC Emergency Operations Center (770-488-7100). Diagnostic information, an image library, and consultations are also available through the CDC DPDx",
"    <a class=\"external\" href=\"file://www.dpd.cdc.gov/\">",
"     web site",
"    </a>",
"    . The Walter Reed Army Institute of Research also provides leishmaniasis diagnostic services through its",
"    <a class=\"external\" href=\"file://wrair-www.army.mil/OtherServices_TropMed_AandW_LDL.aspx\">",
"     Leishmania Diagnostic Laboratory",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Histopathology and culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histopathologic demonstration of parasite requires needle aspiration or biopsy of affected organs. Usually bone marrow or spleen aspirations are performed (sensitivity 70 and 96 percent in one comparative analysis); in Sudanese VL, lymph node aspiration can also be performed, although sensitivity is lower than at the other sites (sensitivity 58 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Splenic aspiration is associated with risk of splenic hemorrhage or bowel perforation. These risks are reported to be low in experienced hands, but the complications can be lethal [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/39,41,42\">",
"     39,41,42",
"    </a>",
"    ]. Splenic aspiration should be performed only if the platelet count and prothrombin times are adequate.",
"   </p>",
"   <p>",
"    Bone marrow aspirates are generally safer than splenic aspirates and in one study the sensitivity of bone marrow examination was found to be proportional to the amount of time spent examining the smear (66 and 92 percent at five minutes and one hour, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Aspirated material should be inoculated into culture and the remainder should be used to prepare a Giemsa stained smear [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/43\">",
"     43",
"    </a>",
"    ]. Biopsy specimens should be prepared with tissue sections as well as touch preparation, which facilitates visualization of intracellular amastigotes in a cell monolayer [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Histopathologic diagnosis requires visualization of amastigotes; these are spherical or ovoid bodies that measure 1 to 5 microns long by 1 to 2 microns wide. Amastigotes are usually found within macrophages but may be seen outside of cells, especially in touch preparations. Amastigotes possess a large nucleus and a prominent deeply stained rod-like organelle called the kinetoplast, made up of tightly concatenated extranuclear DNA. The presence of the kinetoplast is the characteristic that most clearly distinguishes Leishmania amastigotes from Histoplasma, whose size is similar. The parasite load can be quantified based on a scale from 0 (no parasites in 1000 microscopic fields) to 6+ (&gt;100 parasites per microscopic field) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/43\">",
"     43",
"    </a>",
"    ]. Because the number of parasites can vary widely from field to field, quantification requires careful, prolonged examination of the slide (",
"    <a class=\"graphic graphic_picture graphicRef52344 \" href=\"UTD.htm?16/40/17029\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Culture can be performed in Novy-McNeal-Nicolle or other parasitic growth media (available upon request from CDC) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/39\">",
"     39",
"    </a>",
"    ]. Two to three drops of buffy coat, bone marrow, or splenic aspirate are inoculated into the medium. The culture is checked weekly by microscopy for the presence of promastigotes for up to four weeks after inoculation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Growth usually occurs within two weeks but may take longer using material with few parasites. An adaptation using microtiter plates has been successfully applied in India [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/46\">",
"     46",
"    </a>",
"    ]. The sensitivity of culture depends on the parasite load in the sampled material, but is generally 60 to 85 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/44-46\">",
"     44-46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Antibody and antigen tests",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Serum antibody tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Visceral leishmaniasis infection stimulates intense polyclonal B-cell activation, leading to production of a broad array of antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/47\">",
"     47",
"    </a>",
"    ]. Therefore, indirect fluorescent antibody tests (IFA) and enzyme-linked immunosorbent assays (ELISAs) are useful diagnostic tools. The direct agglutination test (DAT) is a diagnostic tool that can be read by eye and therefore requires less equipment than ELISA so can be useful in developing settings [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/48\">",
"     48",
"    </a>",
"    ]. The sensitivity and specificity of serologic assays vary depending on the antigen and format used [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/39,49\">",
"     39,49",
"    </a>",
"    ]. In general, the assays that use whole parasite antigens have high sensitivity but relatively low specificity because of cross-reaction with Chagas disease, malaria and other infections (as well as nonspecific cross-reactivity) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The recombinant kinesin antigen (rK39) is a useful antigen in ELISA assays with high sensitivity and specificity in immunocompetent patients in the Indian subcontinent (92.8 to 100 percent and 96 to 100 percent respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. The sensitivity is lower and more variable in East Africa and Brazil (61.5 to 91 percent), although specificity remains high (&gt;95 percent in Brazil, 90.8 to 98 percent in Africa) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. This antigen has also been adapted for use in immunochromatographic strip format as a rapid test that requires minimal equipment and is easy to use in developing settings [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/39,53,55,56\">",
"     39,53,55,56",
"    </a>",
"    ]. The accuracy of the rK39 tests is comparable to the direct agglutination test (DAT).",
"   </p>",
"   <p>",
"    In regions where VL is endemic, positive antibody test results may be observed among asymptomatic individuals with subclinical infection [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/10,55\">",
"     10,55",
"    </a>",
"    ]. Patients with clinical recovery after successful treatment of VL continue to have positive serology for months to years, so these assays cannot be used as short-term tests of cure [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/10,57\">",
"     10,57",
"    </a>",
"    ]. For these reasons, a positive serological test is not definitive proof of active VL; such results must be interpreted in the context of clinical and epidemiological information.",
"   </p>",
"   <p>",
"    Prior to the development of the assays described above, one early diagnostic tool was the formol-gel (aldehyde) test; placing a drop of formaldehyde in the serum from a patient with VL would cause the specimen to form a gel. However, this finding is observed only when the disease is quite advanced. In Nepal and Uganda the sensitivity was noted to be 40 to 66 percent; specificity was also low [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. This test was widely used from the 1920s until more specific immunological testing became available in the 1980s.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Urine antigen test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most frequently used urine leishmanial antigen assay is the kala-azar latex agglutination test (KAtex). KAtex has high specificity but sensitivity is &lt;70 percent, limiting its diagnostic utility [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/60-62\">",
"     60-62",
"    </a>",
"    ]. Unlike the serologic tests, however, this assay becomes negative rapidly after successful treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Molecular techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polymerase chain reaction (PCR) has been used for diagnosis of VL; many different primer sets, protocols, and visualization methods have been evaluated [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/63-67\">",
"     63-67",
"    </a>",
"    ]. PCR sensitivity is higher than for smear or culture but is variable depending on the tissue used [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. Sensitivity is highest in tissues (eg, spleen or bone marrow); it is more variable in peripheral blood, likely because the circulating parasite load varies with the severity of disease.",
"   </p>",
"   <p>",
"    Molecular techniques are being used increasingly for diagnosis of VL in Europe. In other areas of VL transmission, such techniques are largely limited to research use given limitations in laboratory expertise and equipment [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/67,70,71\">",
"     67,70,71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Leishmanin skin test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The leishmanin skin test (also called the Montenegro skin test) is a tool for assessing the degree of exposure and immunity in a population. In active VL, the test is almost uniformly negative; a positive response usually develops 2 to 24 months after clinical recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/72-75\">",
"     72-75",
"    </a>",
"    ]. Therefore, the test has no role in the diagnosis of VL [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recovered immunocompetent patients usually have strong leishmanin skin test responses; HIV coinfection is associated with anergy to Leishmania antigens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SPECIAL CIRCUMSTANCES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Post kala-azar dermal leishmaniasis",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Post-kala-azar dermal leishmaniasis (PKDL) is a chronic skin rash observed following clinical response to treatment for visceral leishmaniasis due to L. donovani [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]. PKDL usually presents with erythematous or hypopigmented macules that sometimes progress to plaques or nodules (",
"    <a class=\"graphic graphic_picture graphicRef80619 \" href=\"UTD.htm?30/53/31572\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef75252 \" href=\"UTD.htm?38/44/39631\">",
"     picture 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef58427 \" href=\"UTD.htm?41/30/42467\">",
"     picture 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/76\">",
"     76",
"    </a>",
"    ]. The lesions resemble (and must be differentiated from) those of leprosy but are not associated with sensorineural changes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/78\">",
"     78",
"    </a>",
"    ]. Risk factors for progression to PKDL are uncertain but may include immune response to infection, parasite strain, and efficacy of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/77,79,80\">",
"     77,79,80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PKDL has been described among patients in the Horn of Africa and in South Asia. In Sudan, about 50 to 60 percent of patients with VL develop PKDL within six months of treatment; most cases are mild and resolve without further therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/76\">",
"     76",
"    </a>",
"    ]. In South Asia, the incidence of PKDL after VL is about 5 to 10 percent, with an average interval of about two years [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/77,81\">",
"     77,81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;PKDL is diagnosed by microscopy (skin biopsies or slit skin specimens), culture,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    molecular methods [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. In macular lesions, parasites are sparse and may be difficult to detect in smears or histology. Serological tests are often positive in PKDL patients although is uncertain whether positive serology is an indicator of PKDL or a persistent antibody response to the antecedent infection, since serum antibodies can persist for years after treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Serum antibody tests'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The treatment of PKDL is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43625?source=see_link&amp;anchor=H15#H15\">",
"     \"Treatment of visceral leishmaniasis\", section on 'Post kala-azar dermal leishmaniasis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     HIV-VL coinfection",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, patients with HIV-VL coinfection present with the manifestations described in the preceding section. Splenomegaly was observed less frequently observed in the setting of HIV-coinfection (80 versus 97 percent in one series) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/84\">",
"     84",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Visceral leishmaniasis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Among patients with profound immunosuppression (eg, CD4 &lt;50), parasitic infection of atypical sites may occur, including the gastrointestinal tract, peritoneal space, lung, pleural space and skin [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/84-87\">",
"     84-87",
"    </a>",
"    ]. Esophageal involvement can lead to dysphagia and odynophagia, which must be distinguished from other causes of esophagitis such as candidiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/85\">",
"     85",
"    </a>",
"    ]. Mucocutaneous manifestations include non-ulcerative cutaneous lesions that may mimic Kaposi's sarcoma, nodular diffuse leishmaniasis, mucosal lesions, and PKDL [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/87-90\">",
"     87-90",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV-VL coinfected patients tend to have relatively low antibody titers [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/85,91\">",
"     85,91",
"    </a>",
"    ]. In one study, the sensitivity of various serological tests ranged from 25 to 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/92\">",
"     92",
"    </a>",
"    ]. Therefore, histopathologic confirmation is warranted for definitive diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/91\">",
"     91",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Histopathology and culture'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In contrast to serologic tests, molecular techniques tend to have relatively high sensitivity in HIV-VL coinfected patients, since in these individuals the parasite load in peripheral blood specimens is generally high [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/63\">",
"     63",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Molecular techniques'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The treatment of HIV-VL coinfection is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43625?source=see_link&amp;anchor=H13#H13\">",
"     \"Treatment of visceral leishmaniasis\", section on 'HIV coinfection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of visceral leishmaniasis (depending on the presentation and geographical location) may include typhoid fever, acute Chagas disease, malaria, tuberculosis, histoplasmosis, brucellosis, amoebic liver abscess, lymphoma, and other acute bacterial or viral infections [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21161/abstract/9\">",
"     9",
"    </a>",
"    ]. Splenomegaly with prolonged fever and wasting can also occur in the setting of schistosomiasis, myeloproliferative diseases, and tropical splenomegaly due to chronic malaria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Visceral leishmaniasis (VL) is primarily caused by L. donovani and L. infantum (synonym L. chagasi). Leishmania invade and replicate within host macrophages, evading innate and cell-mediated immune responses. Infection generally appears to persist after clinical cure of the primary infection. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many leishmanial infections are asymptomatic, reflecting the ability of the host immune system to control the parasite. The ratio of asymptomatic infection to clinical infection varies widely and may depend on a variety of factors. Most patients with subclinical infection harbor viable parasites lifelong and can develop reactivation disease if immunosuppression occurs. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Asymptomatic infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most important clinical manifestation of VL is the syndrome known as kala-azar (Hindi for \"black fever\"). The incubation period is usually two to six months but can range from a few weeks to several years. Onset of symptoms is usually insidious or subacute, with slow progression of malaise, fever, weight loss, and splenomegaly (with or without hepatomegaly) over a period of months. Less frequently, acute febrile illness can occur with rapidly progressive symptoms. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Visceral leishmaniasis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Definitive diagnosis requires demonstration of the parasite by either histopathology or culture of material obtained by needle aspiration or biopsy from affected organs (usually bone marrow or spleen). Aspirated material should be inoculated into culture and the remainder used to prepare a Giemsa stained smear. Biopsy specimens should be prepared with tissue sections as well as touch preparation. Histopathologic diagnosis requires visualization of amastigotes; culture can be performed in Novy-McNeal-Nicolle or other parasitic growth media. Molecular methods (ie, polymerase chain reaction) can also be used to detect parasite in tissue or peripheral blood. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Histopathology and culture'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Molecular techniques'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serologic tests including indirect fluorescent antibody tests (IFA) and enzyme-linked immunosorbent assays (ELISAs) are useful diagnostic tools. The direct agglutination test (DAT) requires less equipment than ELISA so is useful in developing settings. The recombinant kinesin antigen (rK39) is a useful antigen in ELISA assays as well as in immunochromatographic strip format as a rapid test. A positive serological test is not definitive proof of active VL; such results must be interpreted in the context of clinical and epidemiological information. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Antibody and antigen tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Post-kala-azar dermal leishmaniasis (PKDL) is a chronic skin rash typically observed following clinical response to treatment for visceral leishmaniasis. PKDL occurs in up to 60 percent of VL patients in East Africa and in 5 to 10 percent of VL patients in the Indian subcontinent. PKDL is rare in areas with L. infantum VL. It usually presents with erythematous or hypopigmented macules, which sometimes progress to plaques or nodules. The diagnosis is made by evaluation of skin biopsies or slit skin specimens by microscopy, culture",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      molecular methods. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Post kala-azar dermal leishmaniasis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with HIV-VL coinfection may have a lower incidence of splenomegaly. Among patients with profound immunosuppression parasitic infection of atypical sites may occur, including the gastrointestinal tract, peritoneal space, lung, pleural space, and skin. HIV-VL coinfected patients tend to have relatively low antibody titers but molecular techniques have good sensitivity given generally high levels of parasitemia in peripheral blood specimens. Histopathologic or molecular confirmation is warranted for definitive diagnosis. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'HIV-VL coinfection'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/1\">",
"      Barral A, Badar&oacute; R, Barral-Netto M, et al. Isolation of Leishmania mexicana amazonensis from the bone marrow in a case of American visceral leishmaniasis. Am J Trop Med Hyg 1986; 35:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/2\">",
"      Monroy-Ostria A, Hernandez-Montes O, Barker DC. Aetiology of visceral leishmaniasis in Mexico. Acta Trop 2000; 75:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/3\">",
"      Sacks DL, Kenney RT, Kreutzer RD, et al. Indian kala-azar caused by Leishmania tropica. Lancet 1995; 345:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/4\">",
"      Magill AJ, Gr&ouml;gl M, Gasser RA Jr, et al. Visceral infection caused by Leishmania tropica in veterans of Operation Desert Storm. N Engl J Med 1993; 328:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/5\">",
"      Bogdan C. Mechanisms and consequences of persistence of intracellular pathogens: leishmaniasis as an example. Cell Microbiol 2008; 10:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/6\">",
"      Bogdan C, R&ouml;llinghoff M. The immune response to Leishmania: mechanisms of parasite control and evasion. Int J Parasitol 1998; 28:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/7\">",
"      Murray HW, Oca MJ, Granger AM, Schreiber RD. Requirement for T cells and effect of lymphokines in successful chemotherapy for an intracellular infection. Experimental visceral leishmaniasis. J Clin Invest 1989; 83:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/8\">",
"      Badaro R, Jones TC, Carvalho EM, et al. New perspectives on a subclinical form of visceral leishmaniasis. J Infect Dis 1986; 154:1003.",
"     </a>",
"    </li>",
"    <li>",
"     Jeronimo SM, de Queiroz Sousa A, Pearson RD. Leishmaniasis. In: Tropical infectious diseases: Principles, pathogens and practice, Guerrant RL, Walker DH, Weller PF (Eds), Churchill Livingstone Elsevier, Edinburgh 2006. p.1095.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/10\">",
"      Bern C, Haque R, Chowdhury R, et al. The epidemiology of visceral leishmaniasis and asymptomatic leishmanial infection in a highly endemic Bangladeshi village. Am J Trop Med Hyg 2007; 76:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/11\">",
"      Badar&oacute; R, Jones TC, Loren&ccedil;o R, et al. A prospective study of visceral leishmaniasis in an endemic area of Brazil. J Infect Dis 1986; 154:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/12\">",
"      Moral L, Rubio EM, Moya M. A leishmanin skin test survey in the human population of l'Alacant&iacute; region (Spain): implications for the epidemiology of Leishmania infantum infection in southern Europe. Trans R Soc Trop Med Hyg 2002; 96:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/13\">",
"      Anstead GM, Chandrasekar B, Zhao W, et al. Malnutrition alters the innate immune response and increases early visceralization following Leishmania donovani infection. Infect Immun 2001; 69:4709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/14\">",
"      Blackwell JM, Fakiola M, Ibrahim ME, et al. Genetics and visceral leishmaniasis: of mice and man. Parasite Immunol 2009; 31:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/15\">",
"      Cerf BJ, Jones TC, Badaro R, et al. Malnutrition as a risk factor for severe visceral leishmaniasis. J Infect Dis 1987; 156:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/16\">",
"      Karplus TM, Jeronimo SM, Chang H, et al. Association between the tumor necrosis factor locus and the clinical outcome of Leishmania chagasi infection. Infect Immun 2002; 70:6919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/17\">",
"      de Rossell RA, de Duran RJ, Rossell O, Rodr&iacute;guez AM. Is leishmaniasis ever cured? Trans R Soc Trop Med Hyg 1992; 86:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/18\">",
"      Bern C, Joshi AB, Jha SN, et al. Factors associated with visceral leishmaniasis in Nepal: bed-net use is strongly protective. Am J Trop Med Hyg 2000; 63:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/19\">",
"      Baba CS, Makharia GK, Mathur P, et al. Chronic diarrhea and malabsorption caused by Leishmania donovani. Indian J Gastroenterol 2006; 25:309.",
"     </a>",
"    </li>",
"    <li>",
"     Magill AJ. Visceral leishmaniasis (kala-azar). In: Hunter's Tropical Medicine and Emerging Infectious Diseases, 8th ed, Strickland GT (Ed), W.B.Saunders Company, Philadelphia 2000. p.670.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/21\">",
"      Andrade TM, Carvalho EM, Rocha H. Bacterial infections in patients with visceral leishmaniasis. J Infect Dis 1990; 162:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/22\">",
"      Pagliano P, Carannante N, Rossi M, et al. Visceral leishmaniasis in pregnancy: a case series and a systematic review of the literature. J Antimicrob Chemother 2005; 55:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/23\">",
"      Desjeux P. Leishmaniasis. Public health aspects and control. Clin Dermatol 1996; 14:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/24\">",
"      Sen Gupta, PC. History of kala-azar in India. Indian Medical Gazette 1947; 82:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/25\">",
"      Seaman J, Mercer AJ, Sondorp E. The epidemic of visceral leishmaniasis in western Upper Nile, southern Sudan: course and impact from 1984 to 1994. Int J Epidemiol 1996; 25:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/26\">",
"      Collin S, Davidson R, Ritmeijer K, et al. Conflict and kala-azar: determinants of adverse outcomes of kala-azar among patients in southern Sudan. Clin Infect Dis 2004; 38:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/27\">",
"      Bern C, Hightower AW, Chowdhury R, et al. Risk factors for kala-azar in Bangladesh. Emerg Infect Dis 2005; 11:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/28\">",
"      Rey LC, Martins CV, Ribeiro HB, Lima AA. American visceral leishmaniasis (kala-azar) in hospitalized children from an endemic area. J Pediatr (Rio J) 2005; 81:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/29\">",
"      Pandey K, Sinha PK, Ravidas VN, et al. Nexus of infection with human immunodeficiency virus, pulmonary tuberculosis and visceral leishmaniasis: a case report from Bihar, India. Am J Trop Med Hyg 2005; 72:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/30\">",
"      Herrero M, Orfanos G, Argaw D, et al. Natural history of a visceral leishmaniasis outbreak in highland Ethiopia. Am J Trop Med Hyg 2009; 81:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/31\">",
"      Mueller Y, Mbulamberi DB, Odermatt P, et al. Risk factors for in-hospital mortality of visceral leishmaniasis patients in eastern Uganda. Trop Med Int Health 2009; 14:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/32\">",
"      Duarte MI, Silva MR, Goto H, et al. Interstitial nephritis in human kala-azar. Trans R Soc Trop Med Hyg 1983; 77:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/33\">",
"      Dutra M, Martinelli R, de Carvalho EM, et al. Renal involvement in visceral leishmaniasis. Am J Kidney Dis 1985; 6:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/34\">",
"      Lib&oacute;rio AB, Rocha NA, Oliveira MJ, et al. Acute kidney injury in children with visceral leishmaniasis. Pediatr Infect Dis J 2012; 31:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/35\">",
"      Lima Verde FA, Lima Verde FA, Lima Verde IA, et al. Evaluation of renal function in human visceral leishmaniasis (kala-azar): a prospective study on 50 patients from Brazil. J Nephrol 2007; 20:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/36\">",
"      Costa FA, Guerra JL, Silva SM, et al. CD4(+) T cells participate in the nephropathy of canine visceral leishmaniasis. Braz J Med Biol Res 2000; 33:1455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/37\">",
"      Kager PA, Rees PH. Haematological investigations in visceral leishmaniasis. Trop Geogr Med 1986; 38:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/38\">",
"      Werneck GL, Batista MS, Gomes JR, et al. Prognostic factors for death from visceral leishmaniasis in Teresina, Brazil. Infection 2003; 31:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/39\">",
"      Sundar S, Rai M. Laboratory diagnosis of visceral leishmaniasis. Clin Diagn Lab Immunol 2002; 9:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/40\">",
"      Zijlstra EE, Ali MS, el-Hassan AM, et al. Kala-azar: a comparative study of parasitological methods and the direct agglutination test in diagnosis. Trans R Soc Trop Med Hyg 1992; 86:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/41\">",
"      da Silva MR, Stewart JM, Costa CH. Sensitivity of bone marrow aspirates in the diagnosis of visceral leishmaniasis. Am J Trop Med Hyg 2005; 72:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/42\">",
"      Lightner LK, Chulay JD, Bryceson AD. Comparison of microscopy and culture in the detection of Leishmania donovani from splenic aspirates. Am J Trop Med Hyg 1983; 32:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/43\">",
"      Chulay JD, Bryceson AD. Quantitation of amastigotes of Leishmania donovani in smears of splenic aspirates from patients with visceral leishmaniasis. Am J Trop Med Hyg 1983; 32:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/44\">",
"      Gatti S, Gramegna M, Klersy C, et al. Diagnosis of visceral leishmaniasis: the sensitivities and specificities of traditional methods and a nested PCR assay. Ann Trop Med Parasitol 2004; 98:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/45\">",
"      L&oacute;pez-V&eacute;lez R, Laguna F, Alvar J, et al. Parasitic culture of buffy coat for diagnosis of visceral leishmaniasis in human immunodeficiency virus-infected patients. J Clin Microbiol 1995; 33:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/46\">",
"      Hide M, Singh R, Kumar B, et al. A microculture technique for isolating live Leishmania parasites from peripheral blood of visceral leishmaniasis patients. Acta Trop 2007; 102:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/47\">",
"      Galv&atilde;o-Castro B, S&aacute; Ferreira JA, Marzochi KF, et al. Polyclonal B cell activation, circulating immune complexes and autoimmunity in human american visceral leishmaniasis. Clin Exp Immunol 1984; 56:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/48\">",
"      el Harith A, Kolk AH, Leeuwenburg J, et al. Improvement of a direct agglutination test for field studies of visceral leishmaniasis. J Clin Microbiol 1988; 26:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/49\">",
"      Reed SG, Shreffler WG, Burns JM Jr, et al. An improved serodiagnostic procedure for visceral leishmaniasis. Am J Trop Med Hyg 1990; 43:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/50\">",
"      Badar&oacute; R, Benson D, Eul&aacute;lio MC, et al. rK39: a cloned antigen of Leishmania chagasi that predicts active visceral leishmaniasis. J Infect Dis 1996; 173:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/51\">",
"      Badar&oacute; R, Reed SG, Barral A, et al. Evaluation of the micro enzyme-linked immunosorbent assay (ELISA) for antibodies in American visceral leishmaniasis: antigen selection for detection of infection-specific responses. Am J Trop Med Hyg 1986; 35:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/52\">",
"      Qu JQ, Zhong L, Masoom-Yasinzai M, et al. Serodiagnosis of Asian leishmaniasis with a recombinant antigen from the repetitive domain of a Leishmania kinesin. Trans R Soc Trop Med Hyg 1994; 88:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/53\">",
"      Chappuis F, Rijal S, Soto A, et al. A meta-analysis of the diagnostic performance of the direct agglutination test and rK39 dipstick for visceral leishmaniasis. BMJ 2006; 333:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/54\">",
"      Cunningham J, Hasker E, Das P, et al. A global comparative evaluation of commercial immunochromatographic rapid diagnostic tests for visceral leishmaniasis. Clin Infect Dis 2012; 55:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/55\">",
"      Sundar S, Maurya R, Singh RK, et al. Rapid, noninvasive diagnosis of visceral leishmaniasis in India: comparison of two immunochromatographic strip tests for detection of anti-K39 antibody. J Clin Microbiol 2006; 44:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/56\">",
"      Sundar S, Reed SG, Singh VP, et al. Rapid accurate field diagnosis of Indian visceral leishmaniasis. Lancet 1998; 351:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/57\">",
"      Houghton RL, Petrescu M, Benson DR, et al. A cloned antigen (recombinant K39) of Leishmania chagasi diagnostic for visceral leishmaniasis in human immunodeficiency virus type 1 patients and a prognostic indicator for monitoring patients undergoing drug therapy. J Infect Dis 1998; 177:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/58\">",
"      Chappuis F, Rijal S, Jha UK, et al. Field validity, reproducibility and feasibility of diagnostic tests for visceral leishmaniasis in rural Nepal. Trop Med Int Health 2006; 11:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/59\">",
"      Chappuis F, Mueller Y, Nguimfack A, et al. Diagnostic accuracy of two rK39 antigen-based dipsticks and the formol gel test for rapid diagnosis of visceral leishmaniasis in northeastern Uganda. J Clin Microbiol 2005; 43:5973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/60\">",
"      Boelaert M, El-Safi S, Hailu A, et al. Diagnostic tests for kala-azar: a multi-centre study of the freeze-dried DAT, rK39 strip test and KAtex in East Africa and the Indian subcontinent. Trans R Soc Trop Med Hyg 2008; 102:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/61\">",
"      Sundar S, Agrawal S, Pai K, et al. Detection of leishmanial antigen in the urine of patients with visceral leishmaniasis by a latex agglutination test. Am J Trop Med Hyg 2005; 73:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/62\">",
"      Sundar S, Singh RK, Bimal SK, et al. Comparative evaluation of parasitology and serological tests in the diagnosis of visceral leishmaniasis in India: a phase III diagnostic accuracy study. Trop Med Int Health 2007; 12:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/63\">",
"      Cruz I, Ca&ntilde;avate C, Rubio JM, et al. A nested polymerase chain reaction (Ln-PCR) for diagnosing and monitoring Leishmania infantum infection in patients co-infected with human immunodeficiency virus. Trans R Soc Trop Med Hyg 2002; 96 Suppl 1:S185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/64\">",
"      le Fichoux Y, Quaranta JF, Aufeuvre JP, et al. Occurrence of Leishmania infantum parasitemia in asymptomatic blood donors living in an area of endemicity in southern France. J Clin Microbiol 1999; 37:1953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/65\">",
"      Osman OF, Oskam L, Zijlstra EE, et al. Evaluation of PCR for diagnosis of visceral leishmaniasis. J Clin Microbiol 1997; 35:2454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/66\">",
"      Salotra P, Sreenivas G, Pogue GP, et al. Development of a species-specific PCR assay for detection of Leishmania donovani in clinical samples from patients with kala-azar and post-kala-azar dermal leishmaniasis. J Clin Microbiol 2001; 39:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/67\">",
"      Reithinger R, Dujardin JC. Molecular diagnosis of leishmaniasis: current status and future applications. J Clin Microbiol 2007; 45:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/68\">",
"      Cruz I, Chicharro C, Nieto J, et al. Comparison of new diagnostic tools for management of pediatric Mediterranean visceral leishmaniasis. J Clin Microbiol 2006; 44:2343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/69\">",
"      Antinori S, Calattini S, Longhi E, et al. Clinical use of polymerase chain reaction performed on peripheral blood and bone marrow samples for the diagnosis and monitoring of visceral leishmaniasis in HIV-infected and HIV-uninfected patients: a single-center, 8-year experience in Italy and review of the literature. Clin Infect Dis 2007; 44:1602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/70\">",
"      Raguenaud ME, Jansson A, Vanlerberghe V, et al. Epidemiology and clinical features of patients with visceral leishmaniasis treated by an MSF clinic in Bakool region, Somalia, 2004-2006. PLoS Negl Trop Dis 2007; 1:e85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/71\">",
"      Takagi H, Itoh M, Islam MZ, et al. Sensitive, specific, and rapid detection of Leishmania donovani DNA by loop-mediated isothermal amplification. Am J Trop Med Hyg 2009; 81:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/72\">",
"      Bern C, Amann J, Haque R, et al. Loss of leishmanin skin test antigen sensitivity and potency in a longitudinal study of visceral leishmaniasis in Bangladesh. Am J Trop Med Hyg 2006; 75:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/73\">",
"      MANSON-BAHR PE. Immunity in kala-azar. Trans R Soc Trop Med Hyg 1961; 55:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/74\">",
"      Zijlstra EE, el-Hassan AM. Leishmanin and tuberculin sensitivity in leishmaniasis in the Sudan, with special reference to kala-azar. Trans R Soc Trop Med Hyg 1993; 87:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/75\">",
"      Neogy AB, Nandy A, Dastidar BG, Chowdhury AB. Leishmanin test in Indian kala-azar. Trans R Soc Trop Med Hyg 1986; 80:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/76\">",
"      Zijlstra EE, Musa AM, Khalil EA, et al. Post-kala-azar dermal leishmaniasis. Lancet Infect Dis 2003; 3:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/77\">",
"      Ramesh V, Mukherjee A. Post-kala-azar dermal leishmaniasis. Int J Dermatol 1995; 34:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/78\">",
"      Ramesh V. On the differences between post-kala-azar dermal leishmaniasis and leprosy. Trop Doct 1994; 24:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/79\">",
"      Ansari NA, Ramesh V, Salotra P. Interferon (IFN)-gamma , tumor necrosis factor-alpha , interleukin-6, and IFN-gamma receptor 1 are the major immunological determinants associated with post-kala azar dermal leishmaniasis. J Infect Dis 2006; 194:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/80\">",
"      Sreenivas G, Raju BV, Singh R, et al. DNA polymorphism assay distinguishes isolates of Leishmania donovani that cause kala-azar from those that cause post-kala-azar dermal Leishmaniasis in humans. J Clin Microbiol 2004; 42:1739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/81\">",
"      Rahman KM, Islam S, Rahman MW, et al. Increasing incidence of post-kala-azar dermal leishmaniasis in a population-based study in Bangladesh. Clin Infect Dis 2010; 50:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/82\">",
"      Salotra P, Singh R. Challenges in the diagnosis of post kala-azar dermal leishmaniasis. Indian J Med Res 2006; 123:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/83\">",
"      Salotra P, Sreenivas G, Beena KR, et al. Parasite detection in patients with post kala-azar dermal leishmaniasis in India: a comparison between molecular and immunological methods. J Clin Pathol 2003; 56:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/84\">",
"      Pintado V, Mart&iacute;n-Rabad&aacute;n P, Rivera ML, et al. Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. A comparative study. Medicine (Baltimore) 2001; 80:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/85\">",
"      Alvar J, Ca&ntilde;avate C, Guti&eacute;rrez-Solar B, et al. Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev 1997; 10:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/86\">",
"      Rosenthal E, Marty P, del Giudice P, et al. HIV and Leishmania coinfection: a review of 91 cases with focus on atypical locations of Leishmania. Clin Infect Dis 2000; 31:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/87\">",
"      Machado MP. Cutaneous Leishmaniasis Coinfection in AIDS Patients: Case Report and Literature Review. Braz J Infect Dis 1997; 1:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/88\">",
"      Gonz&aacute;lez-Beato MJ, Moyano B, S&aacute;nchez C, et al. Kaposi's sarcoma-like lesions and other nodules as cutaneous involvement in AIDS-related visceral leishmaniasis. Br J Dermatol 2000; 143:1316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/89\">",
"      C&aacute;novas DL, Carbonell J, Torres J, et al. Laryngeal leishmaniasis as initial opportunistic disease in HIV infection. J Laryngol Otol 1994; 108:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/90\">",
"      Miralles ES, N&uacute;&ntilde;ez M, Hilara Y, et al. Mucocutaneous leishmaniasis and HIV. Dermatology 1994; 189:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/91\">",
"      Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21161/abstract/92\">",
"      Medrano FJ, Ca&ntilde;avate C, Leal M, et al. The role of serology in the diagnosis and prognosis of visceral leishmaniasis in patients coinfected with human immunodeficiency virus type-1. Am J Trop Med Hyg 1998; 59:155.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5732 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-6DAE62D42F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_42_21161=[""].join("\n");
var outline_f20_42_21161=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Asymptomatic infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Visceral leishmaniasis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Viscerotropic disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24542225\">",
"      - Renal impairment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Histopathology and culture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Antibody and antigen tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Serum antibody tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Urine antigen test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Molecular techniques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Leishmanin skin test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SPECIAL CIRCUMSTANCES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Post kala-azar dermal leishmaniasis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      HIV-VL coinfection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/5732\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5732|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/40/17029\" title=\"picture 1\">",
"      Leish bone marrow biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/53/31572\" title=\"picture 2\">",
"      PKDL macules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/44/39631\" title=\"picture 3\">",
"      Papular PKDL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/30/42467\" title=\"picture 4\">",
"      PKDL plaques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5732|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/56/14221\" title=\"table 1\">",
"      Visceral leishmaniasis species",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43625?source=related_link\">",
"      Treatment of visceral leishmaniasis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_42_21162="Clinical manifestations and diagnosis of alcoholic fatty liver disease and alcoholic cirrhosis";
var content_f20_42_21162=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of alcoholic fatty liver disease and alcoholic cirrhosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/42/21162/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/42/21162/contributors\">",
"     Scott L Friedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/42/21162/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/42/21162/contributors\">",
"     Bruce A Runyon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/42/21162/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/42/21162/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/42/21162/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 29, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Excessive alcohol consumption is associated with a range of hepatic manifestations, including alcoholic fatty liver disease (with or without steatohepatitis), alcoholic hepatitis, and cirrhosis. Patients with an alcohol intake of 30 or more grams per day are at increased risk of cirrhosis, although the majority of patients will not develop cirrhosis despite heavy alcohol intake (point prevalence of 1 percent for those who drink 30 to 60",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    and 6 percent for those who drink 120",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21162/abstract/1\">",
"     1",
"    </a>",
"    ]. Unfortunately, among those who do develop liver disease, symptoms often develop only after severe, life-threatening liver disease has already developed.",
"   </p>",
"   <p>",
"    This topic will review the clinical manifestations and diagnosis of alcoholic fatty liver disease and alcoholic cirrhosis. The management of alcoholic liver disease, the pathogenesis of alcoholic liver disease, and the approach to patients with alcoholic hepatitis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22104?source=see_link\">",
"     \"Prognosis and management of alcoholic fatty liver disease and alcoholic cirrhosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17337?source=see_link\">",
"     \"Overview of the complications, prognosis, and management of cirrhosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/5/30807?source=see_link\">",
"     \"Pathogenesis of alcoholic liver disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/4/28744?source=see_link\">",
"     \"Alcoholic hepatitis: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/43/698?source=see_link\">",
"     \"Alcoholic hepatitis: Natural history and management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/2/5160?source=see_link\">",
"     \"Liver transplantation in alcoholic liver disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In 2010, the American Association for the Study of Liver Diseases and the American College of Gastroenterology issued a",
"    <a class=\"external\" href=\"file://www.aasld.org/practiceguidelines/Documents/Bookmarked Practice Guidelines/AlcoholicLiverDisease1-2010.pdf\">",
"     joint guideline",
"    </a>",
"    for the evaluation and management of patients with alcoholic liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21162/abstract/2\">",
"     2",
"    </a>",
"    ]. Another",
"    <a class=\"external\" href=\"file://www.easl.eu/assets/application/files/5e1b5512fb2cabb_file.pdf\">",
"     guideline",
"    </a>",
"    was published in 2012 by the European Association for the Study of the Liver [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21162/abstract/3\">",
"     3",
"    </a>",
"    ]. The discussion that follows is generally consistent with these guidelines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1686233\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alcohol abuse is common world-wide, with an estimated lifetime prevalence of 18 percent among adults in the United States. The National Institutes of Health estimates that in the United States in 2009, there were more than 31,000 deaths from cirrhosis and that alcohol played a role in 48 percent of those deaths (age-adjusted death rate of 4.5 deaths per 100,000 population) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21162/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/22/2409?source=see_link&amp;anchor=H4#H4\">",
"     \"Alcohol abuse and dependence: Epidemiology, clinical manifestations, and diagnosis\", section on 'Adults'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rates of alcoholic liver disease are higher in areas with greater per capita alcohol consumption compared with areas with low levels of consumption. Areas with high rates of alcohol consumption and alcoholic liver disease include Eastern Europe, Southern Europe, and the United Kingdom [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21162/abstract/5\">",
"     5",
"    </a>",
"    ]. On the other hand, countries with large Muslim populations have the lowest rates of alcohol consumption and alcoholic liver disease. The United States is intermediate in its level of consumption (9.4 L per adult per year, compared with 13.4 L per year in the United Kingdom and 0.6 L per year in Indonesia).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17187132\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alcohol abuse may lead to steatosis, steatohepatitis, cirrhosis, and hepatocellular carcinoma. Hepatic steatosis is seen in approximately 90 percent of heavy drinkers and is typically macrovesicular [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21162/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. It may be seen within two weeks of regular alcohol ingestion and resolves rapidly with abstinence [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21162/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. In a study of four patients with normal baseline liver biopsies, ingestion of 98 to 138 grams of alcohol per day resulted in moderate to marked steatosis in all four after 16 to 18 days [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21162/abstract/9\">",
"     9",
"    </a>",
"    ]. It has been estimated that a third of patients with steatosis will develop hepatic inflammation (steatohepatitis) if they continue to drink [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21162/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once steatohepatitis has developed, the risk of cirrhosis is increased compared with simple steatosis. In one study, over a five-year period, cirrhosis developed in 16 percent of patients with steatohepatitis and in 7 percent of patients with simple steatosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21162/abstract/12\">",
"     12",
"    </a>",
"    ]. Higher rates of progression to cirrhosis are seen among patients with steatohepatitis who continue to drink or who present with symptomatic alcoholic hepatitis (up to 50 percent for both groups) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21162/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]. Overall, it is estimated that 8 to 20 percent of patients with steatosis will eventually progress to cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21162/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hepatic decompensation is common among patients with alcoholic cirrhosis. In a population-based study from Denmark that included 446 patients with alcoholic cirrhosis, the risk of complications (ascites development, variceal bleeding, or hepatic encephalopathy) was about 25 percent after one year and 50 percent after five years [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21162/abstract/18\">",
"     18",
"    </a>",
"    ]. Once hepatic decompensation develops, the expected five-year transplant-free survival rate is 60 percent for those who stop drinking alcohol and 30 percent for those who continue to drink alcohol [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21162/abstract/13,19-21\">",
"     13,19-21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1680453\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of alcoholic liver disease depend on the severity of disease. Patients with simple steatosis are often asymptomatic, patients with alcoholic hepatitis typically present with jaundice, and patients who have developed cirrhosis may have peripheral stigmata of liver disease or signs of hepatic decompensation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23194?source=see_link&amp;anchor=H2#H2\">",
"     \"Diagnostic approach to the patient with cirrhosis\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical manifestations in patients with alcoholic hepatitis are reviewed separately (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/4/28744?source=see_link&amp;anchor=H418822022#H418822022\">",
"     \"Alcoholic hepatitis: Clinical manifestations and diagnosis\", section on 'Clinical manifestations'",
"    </a>",
"    .).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1680526\">",
"    <span class=\"h2\">",
"     Signs and symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with alcoholic fatty liver are typically asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21162/abstract/22\">",
"     22",
"    </a>",
"    ]. Patients who have developed cirrhosis may report jaundice, weakness, peripheral edema, abdominal distension, or symptoms of gastrointestinal bleeding, such as hematemesis or melena. Patients with hepatic encephalopathy may note disturbances in their sleep pattern and confusion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23194?source=see_link&amp;anchor=H2#H2\">",
"     \"Diagnostic approach to the patient with cirrhosis\", section on 'Clinical manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17337?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of the complications, prognosis, and management of cirrhosis\", section on 'Complications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/22/34153?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations and diagnosis of hepatic encephalopathy\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1680566\">",
"    <span class=\"h2\">",
"     Physical examination findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical examination findings in patients with alcoholic liver disease range from a normal physical examination to evidence of cirrhosis with hepatic decompensation (",
"    <a class=\"graphic graphic_table graphicRef82583 \" href=\"UTD.htm?9/25/9627\">",
"     table 1",
"    </a>",
"    ). Patients with steatosis may have a normal examination or hepatomegaly. Patients who have developed cirrhosis may have stigmata of chronic liver disease (eg, spider angiomata, palmar erythema, gynecomastia). With hepatic decompensation, patients may develop ascites, peripheral edema, or hepatic encephalopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23194?source=see_link&amp;anchor=H4#H4\">",
"     \"Diagnostic approach to the patient with cirrhosis\", section on 'Physical findings'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17337?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of the complications, prognosis, and management of cirrhosis\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with alcoholic liver disease often have coexisting dysfunction in other organs and may have signs of cardiomyopathy, neuropathies, pancreatic dysfunction, and skeletal muscle wasting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/53/35672?source=see_link&amp;anchor=H7#H7\">",
"     \"Alcoholic cardiomyopathy\", section on 'Clinical presentation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/24/40328?source=see_link&amp;anchor=H17#H17\">",
"     \"Overview of the chronic neurologic complications of alcohol\", section on 'Clinical features'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/13/30935?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations and diagnosis of chronic pancreatitis in adults\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1681012\">",
"    <span class=\"h2\">",
"     Laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several characteristic laboratory abnormalities in patients with alcoholic liver disease, but none is diagnostic (",
"    <a class=\"graphic graphic_table graphicRef64489 \" href=\"UTD.htm?37/57/38811\">",
"     table 2",
"    </a>",
"    ). The classic finding is moderately elevated transaminases, with an aspartate aminotransferase (AST) to alanine aminotransferase (ALT) ratio &gt;1 (and often &gt;2).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H62649244\">",
"    <span class=\"h3\">",
"     Liver test abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum aminotransferase levels may be normal or moderately elevated in the setting of alcoholic fatty liver disease and alcoholic cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21162/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. The AST elevation is usually less than eight times the upper limit of normal, and the ALT elevation is typically less than five times the upper limit of normal. The degree of elevation does not correlate with the severity of the underlying liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21162/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unlike other forms of liver disease in which the serum ALT level often is higher than the serum AST level, the most common pattern of liver biochemical test abnormalities in alcoholic liver disease is a disproportionate elevation of the AST compared with the ALT, resulting in a ratio greater than one [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21162/abstract/23-27\">",
"     23-27",
"    </a>",
"    ]. As an example, in a study that included 38 patients with alcoholic liver disease, the mean AST was 92 int.",
"    <span class=\"nowrap\">",
"     unit/L,",
"    </span>",
"    and the ALT was 80 int.",
"    <span class=\"nowrap\">",
"     unit/L",
"    </span>",
"    (AST to ALT ratio of 1.2) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21162/abstract/28\">",
"     28",
"    </a>",
"    ]. The relatively lower elevation of serum ALT has been ascribed in part to hepatic deficiency of pyridoxal 5'-phosphate in alcoholics, which is a cofactor for the enzymatic activity of ALT [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21162/abstract/27\">",
"     27",
"    </a>",
"    ]. According to this hypothesis, the altered ratio reflects a failure to appropriately increase the ALT, rather than a disproportionate elevation in AST.",
"   </p>",
"   <p>",
"    An AST to ALT ratio &gt;1 is occasionally seen in patients with nonalcoholic steatohepatitis and is frequently seen in patients who have developed nonalcoholic cirrhosis. However, if the ratio is greater than two, the transaminase elevations are likely due to alcoholic liver disease, since values greater than two are rarely seen in other forms of liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21162/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. In a study of 271 patients with biopsy-confirmed liver disorders, more than 90 percent of the patients whose AST to ALT ratio was &ge;2 had alcoholic liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21162/abstract/29\">",
"     29",
"    </a>",
"    ]. The percentage increased to greater than 96 percent when the ratio was &ge;3. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5446?source=see_link&amp;anchor=H3#H3\">",
"     \"Patterns of plasma aspartate and alanine aminotransferase levels with and without liver disease\", section on 'AST/ALT ratio'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/18/34090?source=see_link\">",
"     \"Approach to the patient with abnormal liver biochemical and function tests\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The gamma-glutamyl transpeptidase (GGT) is often elevated in patients with alcoholic liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21162/abstract/24,30\">",
"     24,30",
"    </a>",
"    ]. In a study that included 123 patients who abused alcohol, all of the patients with liver disease had elevations of the GGT approximately 8 to 10 times the upper limit of normal [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21162/abstract/30\">",
"     30",
"    </a>",
"    ]. The GGT elevations persisted after 8 weeks of abstinence. However, GGT elevations are not specific for alcoholic liver disease. For example, elevated GGT levels may be seen in patients with biliary or pancreatic disease and in patients taking certain medications, such as barbiturates and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19353?source=see_link&amp;anchor=H13#H13\">",
"     \"Enzymatic measures of cholestasis (eg, alkaline phosphatase, 5&rsquo;-nucleotidase, gamma-glutamyl transpeptidase)\", section on 'Gamma-glutamyl transpeptidase'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Elevated bilirubin levels are frequently seen in patients with decompensated cirrhosis from any cause, including alcoholic liver disease. Elevation of the bilirubin in a patient who does not have cirrhosis should raise concern for alcoholic hepatitis. Patients who are malnourished or who have cirrhosis may have low albumin levels. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23194?source=see_link&amp;anchor=H5#H5\">",
"     \"Diagnostic approach to the patient with cirrhosis\", section on 'Laboratory findings'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/4/28744?source=see_link&amp;anchor=H418826776#H418826776\">",
"     \"Alcoholic hepatitis: Clinical manifestations and diagnosis\", section on 'Laboratory tests'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24022?source=see_link&amp;anchor=H3#H3\">",
"     \"Tests of the liver's biosynthetic capacity (eg, albumin, coagulation factors, prothrombin time)\", section on 'Albumin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H62649270\">",
"    <span class=\"h3\">",
"     Hematologic abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematologic findings in patients with alcoholic liver disease may include thrombocytopenia, anemia, an elevated mean corpuscular volume (MCV), a decreased lymphocyte count, an elevated erythrocyte sedimentation rate (ESR), and an elevated international normalized ratio (INR) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21162/abstract/23,31\">",
"     23,31",
"    </a>",
"    ]. Macrocytosis suggests longstanding disease and may result from vitamin B12 or folate deficiency, alcohol toxicity, or increased lipid deposition in red cell membranes. Similarly, thrombocytopenia may result from primary bone marrow hypoplasia (which can be due to alcohol and is usually brief) or splenic sequestration (due to portal hypertension and an enlarged spleen). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4710?source=see_link\">",
"     \"Alcohol abuse and hematologic disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one study that included 40 patients with alcoholic liver disease, the following mean laboratory test results were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21162/abstract/31\">",
"     31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hemoglobin and hematocrit: 12",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      and 33.7 percent, respectively",
"     </li>",
"     <li>",
"      MCV: 91.6 fl",
"     </li>",
"     <li>",
"      Lymphocyte percentage: 24.8 percent",
"     </li>",
"     <li>",
"      ESR: 25.9",
"     </li>",
"     <li>",
"      INR: 1.6",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H62649296\">",
"    <span class=\"h3\">",
"     Other abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional laboratory findings that may be seen in patients who have progressed to cirrhosis include hyponatremia and an elevated creatinine in patients with hepatorenal syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23194?source=see_link&amp;anchor=H5#H5\">",
"     \"Diagnostic approach to the patient with cirrhosis\", section on 'Laboratory findings'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/50/29482?source=see_link&amp;anchor=H4#H4\">",
"     \"Hepatorenal syndrome\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H62649217\">",
"    <span class=\"h2\">",
"     Radiographic imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transabdominal ultrasound, abdominal computed tomography, and abdominal magnetic resonance imaging may show signs of hepatic steatosis or cirrhosis in patients with alcoholic liver disease. (See",
"    <a class=\"local\" href=\"#H62649043\">",
"     'Imaging studies'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1680469\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alcoholic liver disease may be suspected in a patient with a compatible history who has elevated serum transaminases, a suggestion of fatty liver on imaging tests, or is found to have steatosis on liver biopsy. Liver tests are generally normal or modestly elevated, and jaundice is unusual. The diagnosis is established after excluding other causes of fatty liver or cirrhosis. (See",
"    <a class=\"local\" href=\"#H76346509\">",
"     'When to consider alcoholic liver disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Our general approach to the diagnosis of alcoholic liver disease is consistent with a 2010",
"    <a class=\"external\" href=\"file://www.aasld.org/practiceguidelines/Documents/Bookmarked Practice Guidelines/AlcoholicLiverDisease1-2010.pdf\">",
"     guideline",
"    </a>",
"    from the American Association for the Study of Liver Diseases and the American College of Gastroenterology (",
"    <a class=\"graphic graphic_table graphicRef63838 \" href=\"UTD.htm?25/32/26123\">",
"     table 3",
"    </a>",
"    ) and a 2012",
"    <a class=\"external\" href=\"file://www.easl.eu/assets/application/files/5e1b5512fb2cabb_file.pdf\">",
"     guideline",
"    </a>",
"    from the European Association for the Study of Liver [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21162/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The evaluation includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obtaining a very detailed history to quantify alcohol use and drinking patterns and to identify other potential sources of hepatic injury (see",
"      <a class=\"local\" href=\"#H2\">",
"       'History'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Performing a physical examination to identify stigmata of chronic liver disease (see",
"      <a class=\"local\" href=\"#H61973941\">",
"       'Physical examination'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Obtaining laboratory tests to look for signs of hepatitic inflammation and to assess hepatic synthetic function, including (see",
"      <a class=\"local\" href=\"#H61974500\">",
"       'Standard laboratory evaluation'",
"      </a>",
"      below):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Liver blood tests &ndash; transaminases, bilirubin, alkaline phosphatase, gamma-glutamyl transaminase",
"     </li>",
"     <li>",
"      Complete blood count",
"     </li>",
"     <li>",
"      Serum albumin level",
"     </li>",
"     <li>",
"      Coagulation studies &ndash; prothrombin time, INR",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obtaining laboratory tests to identify other causes of chronic hepatic injury, including (see",
"      <a class=\"local\" href=\"#H61974447\">",
"       'Tests for other causes of liver disease'",
"      </a>",
"      below):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Hepatitis B surface antigen, anti-hepatitis B core IgG",
"     </li>",
"     <li>",
"      Antibodies to hepatitis C virus (HCV)",
"     </li>",
"     <li>",
"      Serum ferritin and transferrin saturation for hemochromatosis",
"     </li>",
"     <li>",
"      Total IgG or gamma-globulin level, antinuclear antibody, anti-smooth muscle antibody,",
"      <span class=\"nowrap\">",
"       anti-liver/kidney",
"      </span>",
"      microsomal-1 (anti-LKM-1) antibodies for autoimmune hepatitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinical and laboratory features are often adequate for establishing the diagnosis of alcoholic liver disease in a patient with a history of significant alcohol use, provided the patient does not have risk factors for other causes of liver disease and testing for other common causes of liver disease is negative. In a study of patients with chronically elevated liver biochemical tests, the sensitivity and specificity of clinical findings for diagnosing alcoholic liver disease were 91 and 97 percent, respectively, when liver biopsy was used as the gold standard [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21162/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Liver imaging may provide evidence of hepatic steatosis or cirrhosis, but it is not able to differentiate alcoholic liver disease from other causes. Ultrasound is always indicated to confirm that the liver is homogeneous and to exclude other causes of abnormal liver tests (eg, biliary obstruction, hepatic masses). More detailed liver imaging (eg, computed tomography or magnetic resonance imaging) is obtained for patients with suspected cirrhosis or ultrasound evidence of biliary tract obstruction (eg, jaundice, elevation of liver tests in a cholestatic pattern). (See",
"    <a class=\"local\" href=\"#H62649043\">",
"     'Imaging studies'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A liver biopsy may be required if the diagnosis remains uncertain following a noninvasive evaluation. In addition, it can establish the severity of liver disease. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Liver biopsy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H76346509\">",
"    <span class=\"h2\">",
"     When to consider alcoholic liver disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alcoholic liver disease should be suspected in patients with a history of significant alcohol consumption who present with:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Abnormal transaminases (particularly if the AST is greater than the ALT)",
"     </li>",
"     <li>",
"      Hepatomegaly",
"     </li>",
"     <li>",
"      Radiographic imaging suggesting hepatic steatosis or",
"      <span class=\"nowrap\">",
"       fibrosis/cirrhosis",
"      </span>",
"     </li>",
"     <li>",
"      A liver biopsy showing steatosis or cirrhosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several definitions have been proposed for what constitutes significant alcohol consumption [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21162/abstract/33\">",
"     33",
"    </a>",
"    ]. We define significant alcohol consumption as an average consumption of &gt;210 grams of alcohol per week in men or &gt;140 grams of alcohol per week in women over at least a two-year period, a definition that is consistent with a 2012",
"    <a class=\"external\" href=\"file://www.gastro.org/practice/medical-position-statements\">",
"     joint guideline",
"    </a>",
"    from the American Gastroenterological Association, the American Association for the Study of Liver Diseases, and the American College of Gastroenterology [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21162/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A standard drink in the United States (12 oz [360 mL] of beer, 5 oz [150 mL] of wine, 1.5 oz [45 mL] of 80-proof spirits) contains approximately 14 grams of alcohol (",
"    <a class=\"graphic graphic_figure graphicRef56818 \" href=\"UTD.htm?20/18/20778\">",
"     figure 1",
"    </a>",
"    ), so the limits above roughly translate to &gt;15 drinks per week for men and &gt;10 drinks per week for women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history should include questioning to assess a patient's alcohol use and to elicit risk factors for other causes of liver disease. Obtaining an accurate alcohol use history in patients with suspected alcoholic liver disease can be difficult, since many patients do not readily admit to heavy alcohol use. In some cases, speaking with the patient's family or friends may help in obtaining a more accurate history. Patients should be asked about their pattern of alcohol use, the type of alcohol consumed, and the amount of alcohol ingested. Several screening tools exist to identify patients who abuse alcohol. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/24/25993?source=see_link&amp;anchor=H2788947#H2788947\">",
"     \"Screening for unhealthy use of alcohol and other drugs\", section on 'Screening tests'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H9\">",
"     'Differential diagnosis'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/18/34090?source=see_link\">",
"     \"Approach to the patient with abnormal liver biochemical and function tests\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    To identify risk factors for other causes of liver disease, the patient should also be carefully questioned about medication use (including herbal supplements and over the counter medications), possible parenteral exposures to viral hepatitis (including transfusions, intravenous and intranasal drug use, tattoos, and sexual activity), occupational exposures to hepatotoxins, family history of liver disease, and whether the patient has a history of diseases that may be associated with liver disease (such as the metabolic syndrome, celiac disease, or autoimmune disorders). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/18/34090?source=see_link\">",
"     \"Approach to the patient with abnormal liver biochemical and function tests\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61973941\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with suspected alcoholic liver disease should be examined for hepatomegaly and signs of chronic liver disease, such as spider angiomata, ascites, splenomegaly, and gynecomastia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23194?source=see_link&amp;anchor=H4#H4\">",
"     \"Diagnostic approach to the patient with cirrhosis\", section on 'Physical findings'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Physical findings in patients with alcoholic liver disease may vary from normal to evidence of cirrhosis or hepatic decompensation (",
"    <a class=\"graphic graphic_table graphicRef82583 \" href=\"UTD.htm?9/25/9627\">",
"     table 1",
"    </a>",
"    ). Patients with alcoholic liver disease may also have extrahepatic manifestations of alcohol abuse, such as cardiomyopathy, neuropathies, pancreatitis, and skeletal muscle wasting. As a result, a thorough physical examination should be carried out to identify problems outside of the liver. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/61/38874?source=see_link&amp;anchor=H8#H8\">",
"     \"Overview of the risks and benefits of alcohol consumption\", section on 'Alcohol and specific illnesses'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/53/35672?source=see_link\">",
"     \"Alcoholic cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/24/40328?source=see_link\">",
"     \"Overview of the chronic neurologic complications of alcohol\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H62648107\">",
"    <span class=\"h2\">",
"     Laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory testing in patients with suspected alcoholic liver disease includes testing for evidence of hepatitis and liver synthetic dysfunction. In addition, patients should be tested for other causes of liver disease that may co-exist with alcoholic liver disease or may offer alternative explanations for a patient's liver disease. There are several characteristic laboratory abnormalities in patients with alcoholic liver disease, but none is diagnostic (",
"    <a class=\"graphic graphic_table graphicRef64489 \" href=\"UTD.htm?37/57/38811\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H1681012\">",
"     'Laboratory tests'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61974500\">",
"    <span class=\"h3\">",
"     Standard laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory tests that should be obtained in patients with suspected alcoholic liver disease include liver tests (serum transaminases, bilirubin, alkaline phosphatase, gamma-glutamyl transaminase), a complete blood count, serum albumin, and coagulation studies (prothrombin time, INR). In addition, patients with ascites should undergo paracentesis to confirm that the ascites is due to portal hypertension (serum-to-ascites albumin gradient &ge;1.1",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    [11",
"    <span class=\"nowrap\">",
"     g/L]).",
"    </span>",
"    (See",
"    <a class=\"local\" href=\"#H1681012\">",
"     'Laboratory tests'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/43/14010?source=see_link&amp;anchor=H56451750#H56451750\">",
"     \"Evaluation of adults with ascites\", section on 'Determining the cause of the ascites'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no laboratory tests that reliably differentiate alcoholic liver disease from other causes of liver disease. However, an aspartate aminotransferase (AST) to alanine aminotransferase (ALT) ratio &gt;2 is highly suggestive of alcoholic liver disease. (See",
"    <a class=\"local\" href=\"#H62649244\">",
"     'Liver test abnormalities'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61974447\">",
"    <span class=\"h3\">",
"     Tests for other causes of liver disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with suspected alcoholic liver disease should also be tested for other causes of hepatitis that may be responsible for the patients liver disease or may co-exist with alcoholic liver disease. The combination of alcohol use with other liver diseases such as hereditary hemochromatosis, nonalcoholic steatohepatitis, chronic viral hepatitis, and autoimmune liver disease can lead to an accelerated rate of fibrosis compared with the disorders in isolation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21162/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In order to rule out other common causes of chronic hepatitis, patients should be tested for the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hepatitis B surface antigen, anti-hepatitis B core IgG",
"     </li>",
"     <li>",
"      Antibodies to hepatitis C virus (HCV)",
"     </li>",
"     <li>",
"      Serum ferritin and transferrin saturation for hemochromatosis",
"     </li>",
"     <li>",
"      Total IgG or gamma-globulin level, antinuclear antibody, anti-smooth muscle antibody,",
"      <span class=\"nowrap\">",
"       anti-liver/kidney",
"      </span>",
"      microsomal-1 (anti-LKM-1) antibodies for autoimmune hepatitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Ferritin production and the plasma ferritin concentration are increased in the absence of iron overload in certain liver diseases, including alcoholic liver disease and acute or subacute hepatitis (from any cause) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21162/abstract/36\">",
"     36",
"    </a>",
"    ]. As a result, in patients with acute or subacute hepatitis testing should be deferred until the patient has recovered from the acute episode. In addition, the serum transferrin saturation in alcoholic liver disease may reach or exceed 60 percent, perhaps because alcohol suppresses liver transferrin synthesis. As a result, if ferritin levels or the transferrin saturation are high, additional testing for hemochromatosis is indicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/19/35129?source=see_link&amp;anchor=H5#H5\">",
"     \"Pathophysiology and diagnosis of iron overload syndromes\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/19/35129?source=see_link&amp;anchor=H17#H17\">",
"     \"Pathophysiology and diagnosis of iron overload syndromes\", section on 'Distinction from alcoholic liver disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional testing will depend upon the patient's symptoms and risk factors for other causes of liver disease and may include testing for (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/18/34090?source=see_link\">",
"     \"Approach to the patient with abnormal liver biochemical and function tests\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Non-alcoholic fatty liver disease (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38105?source=see_link\">",
"       \"Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Wilson disease (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13018?source=see_link&amp;anchor=H65234572#H65234572\">",
"       \"Clinical manifestations, diagnosis, and natural history of Wilson disease\", section on 'When to consider Wilson disease'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Alpha-1-antitrypsin deficiency (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/8/6281?source=see_link&amp;anchor=H13#H13\">",
"       \"Clinical manifestations, diagnosis, and natural history of alpha-1 antitrypsin deficiency\", section on 'Diagnosis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Hyperthyroidism (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26520?source=see_link&amp;anchor=H25975024#H25975024\">",
"       \"Diagnosis of hyperthyroidism\", section on 'Clinical manifestations'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Celiac disease (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40650?source=see_link&amp;anchor=H15#H15\">",
"       \"Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults\", section on 'Clinical manifestations'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Primary biliary cirrhosis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41641?source=see_link&amp;anchor=H3#H3\">",
"       \"Clinical manifestations, diagnosis, and natural history of primary biliary cirrhosis\", section on 'Clinical manifestations at presentation'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Primary sclerosing cholangitis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/63/22521?source=see_link&amp;anchor=H2#H2\">",
"       \"Clinical manifestations and diagnosis of primary sclerosing cholangitis\", section on 'Clinical manifestations'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In some cases, if the clinical picture is only partially consistent with alcoholic liver disease (eg, liver disease in a patients with moderate alcohol use or an AST to ALT ratio &lt;1), but no alternative causes are identified noninvasively, a liver biopsy may be required. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Liver biopsy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H62649043\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging studies can be used to assess for hepatic parenchymal changes, but they cannot confirm that the changes are the result of alcoholic liver disease. Ultrasound, computed tomography (CT), and magnetic resonance imaging (MRI) can be used to diagnose fatty change, cirrhosis, or neoplastic diseases of the liver. They can also rule out obstructive biliary pathology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H62649741\">",
"    <span class=\"h3\">",
"     Ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasound can detect hepatic steatosis but will miss many patients with &lt;30 percent steatosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21162/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. Ultrasonography in patients with fatty liver may reveal a liver with a hyperechoic texture [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21162/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. In patients with fibrosis, the ultrasound may reveal a coarse echo pattern. If cirrhosis has developed, nodules may be seen, causing an irregular outline of the liver surface.",
"   </p>",
"   <p>",
"    Studies of ultrasound for evaluation of hepatic steatosis and fibrosis have found the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 235 patients with suspected liver disease, the sensitivity of a hyperechoic pattern on ultrasound for hepatic steatosis was 64 percent, with a specificity of 97 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?20/42/21162/abstract/37\">",
"       37",
"      </a>",
"      ]. Among patients with &ge;30 percent steatosis, the sensitivity was 91 percent, with a specificity of 93 percent.",
"     </li>",
"     <li>",
"      In a study that included 35 patients with significant hepatic fibrosis (advanced fibrosis or cirrhosis), the sensitivity of ultrasound for significant fibrosis was 57 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?20/42/21162/abstract/38\">",
"       38",
"      </a>",
"      ]. Among patients with established cirrhosis, the sensitivity was 71 percent. The overall specificity was 88 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H76345480\">",
"    <span class=\"h3\">",
"     Computed tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatic steatosis is readily detected by CT scan [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21162/abstract/40\">",
"     40",
"    </a>",
"    ]. Liver attenuation in patients with hepatic steatosis is lower than that seen in the spleen. On non-contrast-enhanced images, the attenuation value of normal liver is between 45 and 65 HU and is typically 8 HU higher than that of the spleen. However, in patients with hepatic steatosis, the attenuation value of the liver is typically 10 to 25 HU less than the spleen. With severe steatosis, liver attenuation may be less than unenhanced hepatic venous structures. The relative densities of the liver and spleen are highly variable on contrast-enhanced CT, so the diagnosis of steatosis is based on non-contrast-enhanced images.",
"   </p>",
"   <p>",
"    CT findings in patients with cirrhosis may include atrophy of the right lobe of the liver, hypertrophy of the caudate lobe, hypertrophy of the lateral segment of the left lobe, parenchymal nodularity, attenuation of hepatic vasculature, splenomegaly, venous collaterals, and ascites [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21162/abstract/41\">",
"     41",
"    </a>",
"    ]. In some cases, the liver may be diffusely atrophic or hepatomegaly may be seen.",
"   </p>",
"   <p>",
"    In a study that included 35 patients with cirrhosis (20 patients), alcoholic hepatitis alone (1 patient), or hepatic steatosis (14 patients) along with 10 control patients, CT scan had a sensitivity for cirrhosis of 78 percent and for fatty liver of 81 percent. There was only one control patient with false positive results (specificity of 90 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H76345538\">",
"    <span class=\"h3\">",
"     Magnetic resonance imaging and spectroscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gradient echo magnetic resonance (MR) pulse sequences are sensitive for detecting hepatic steatosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21162/abstract/40\">",
"     40",
"    </a>",
"    ]. Water and fat are imaged in and out of phase. With in-phase imaging, the signal intensities are additive, whereas when out-of-phase, the signal intensities cancel each other out. If there is a significant amount of intracellular fat, the signal intensity on the out-of-phase images will be lower than that seen on the in-phase images. In a study of 33 patients with diabetes (and thus at risk for nonalcoholic fatty liver disease), the sensitivity of in-phase and out-of-phase MRI for hepatic steatosis was 95 percent, with a sensitivity of 98 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21162/abstract/42\">",
"     42",
"    </a>",
"    ]. On T1-weighted and T2-weighted images, focal hepatic steatosis may result in higher signal intensity compared with normal liver.",
"   </p>",
"   <p>",
"    Regenerative nodules in patients with cirrhosis may appear hypointense, isointense, or hyperintense related to the background liver on T1-weighted images [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21162/abstract/41\">",
"     41",
"    </a>",
"    ]. On T2-weighted images, the signal intensity of the regenerative nodules does not increase (unlike hepatocellular carcinoma). The nodules on T2-weighted images are often hypointense or isointense.",
"   </p>",
"   <p>",
"    On MRI, specific features that are suggestive of alcoholic cirrhosis versus cirrhosis from viral hepatitis include a higher volume index of the caudate lobe, smaller size of regenerative nodules of the liver, and more frequent visualization of the right posterior hepatic notch [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21162/abstract/43\">",
"     43",
"    </a>",
"    ]. In a study that included 23 patients with chronic hepatitis, diffusion-weighted MRI had a sensitivity for detecting advanced fibrosis or cirrhosis of 83 percent, with a specificity of 80 percent.",
"   </p>",
"   <p>",
"    MR spectroscopy is a specialized MRI sequence that allows assessment of the chemical composition of tissue. Proton MR spectroscopy can be used to quantify lipid content [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21162/abstract/44\">",
"     44",
"    </a>",
"    ]. It has been used to estimate hepatic fat volume fractions and correlates well with histology [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21162/abstract/45\">",
"     45",
"    </a>",
"    ]. However, the technique is not widely available.",
"   </p>",
"   <p>",
"    An experimental tool for diagnosing alcoholic liver disease is hepatic phosphorus 31 magnetic resonance spectroscopy, which can calculate hepatic energy metabolism and phospholipid membrane metabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21162/abstract/46\">",
"     46",
"    </a>",
"    ]. Patients with cirrhosis from alcohol have lower phosphodiesterase to adenosine triphosphate (ATP) ratios than patients with cirrhosis from other causes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21162/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H76346075\">",
"    <span class=\"h3\">",
"     Other noninvasive methods to detect fibrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other methods for the detection of hepatic fibrosis, including transient elastography and magnetic resonance elastography, are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/59/30650?source=see_link\">",
"     \"Noninvasive assessment of hepatic fibrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Liver biopsy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H73664414\">",
"    <span class=\"h3\">",
"     Patients who may need a liver biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical and laboratory features are often adequate for establishing the diagnosis of alcoholic liver disease in a patient with a history of significant alcohol use, provided the patient does not have risk factors for other causes of liver disease and testing for other common causes of hepatitis is negative. However, a liver biopsy may be required if the diagnosis remains uncertain following a noninvasive evaluation. In addition, it can establish the severity of liver disease.",
"   </p>",
"   <p>",
"    The decision to perform a biopsy should consider the confidence of the clinical diagnosis and the role that the biopsy findings would have in guiding therapeutic options. As a general rule, a biopsy may be indicated in:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Any patient with serum aminotransferase elevations that persist for more than six months without a clear explanation, even if the patient is asymptomatic.",
"     </li>",
"     <li>",
"      Patients who have elevated aminotransferases and evidence of clinically significant hepatic dysfunction (eg, abnormal prothrombin time, hypoalbuminemia). If a coagulopathy is present, transjugular biopsy is usually safer than percutaneous biopsy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/37/9814?source=see_link\">",
"       \"Transjugular liver biopsy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients in whom the diagnosis of alcoholic liver disease is uncertain based on clinical and laboratory findings.",
"     </li>",
"     <li>",
"      Patients who may have more than one type of liver disease (such as alcohol and hepatitis C) in whom a liver biopsy may help determine the relative contribution of these factors (",
"      <a class=\"graphic graphic_picture graphicRef55740 \" href=\"UTD.htm?29/26/30119\">",
"       picture 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Patients in whom a more detailed understanding of prognosis is desired. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22104?source=see_link&amp;anchor=H5#H5\">",
"       \"Prognosis and management of alcoholic fatty liver disease and alcoholic cirrhosis\", section on 'Natural history and prognostic factors'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1683016\">",
"    <span class=\"h3\">",
"     Histologic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early changes in patients with alcoholic liver disease seen under the electron microscope include accumulation of membrane-bound large droplet (macrovesicular) steatosis, proliferation of smooth endoplasmic reticulum, and gradual distortion of mitochondria [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21162/abstract/48\">",
"     48",
"    </a>",
"    ]. This is most often seen in the pericentral region of hepatic lobules (zone 3) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21162/abstract/49\">",
"     49",
"    </a>",
"    ]. Fat accumulation can be seen easily by light microscopy; inflammatory changes are minimal at this stage apart from occasional lipogranulomata in pericentral zones [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21162/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fat in alcoholic liver disease is typically macrovesicular and composed of neutral triglycerides. However, small droplets of triglycerides may resemble microvesicular fat (and indeed are sometimes referred to as such on pathology reports) but are not the same as the lipid droplets that form microvesicular fat in other disorders such as acute fatty liver of pregnancy (",
"    <a class=\"graphic graphic_picture graphicRef80340 \" href=\"UTD.htm?11/55/12153\">",
"     picture 2",
"    </a>",
"    ),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    toxicity, and Reye's syndrome. Microvesicular fat in these conditions (which is composed of free fatty acids that are hepatotoxic) can only be detected by special stains and not on standard light microscopy.",
"   </p>",
"   <p>",
"    Steatosis may progress to steatohepatitis. As with steatosis, inflammation is typically first seen in zone 3. As the disease progresses, the histologic changes may extend to the portal tracts. The findings may vary among patients with regard to their extent and severity. The presence of neutrophils is a hallmark of alcoholic steatohepatitis and is unusual in chronic viral hepatitis. Their role in pathogenesis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/5/30807?source=see_link\">",
"     \"Pathogenesis of alcoholic liver disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mallory-Denk bodies (previously called Mallory bodies or Mallory's hyaline) are eosinophilic accumulations of intracellular protein aggregates within the cytoplasm of hepatocytes (",
"    <a class=\"graphic graphic_picture graphicRef75188 \" href=\"UTD.htm?33/52/34628\">",
"     picture 4B",
"    </a>",
"    ). They represent condensations of intracellular \"intermediate filaments\" or cytokeratins that are normal components of the hepatocyte cytoskeleton [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21162/abstract/51\">",
"     51",
"    </a>",
"    ]. The mechanisms underlying Mallory-Denk body formation in alcoholic liver disease are unclear. Furthermore, they are not specific for alcoholic steatohepatitis and can be seen in nonalcoholic steatohepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21162/abstract/52\">",
"     52",
"    </a>",
"    ], Indian childhood cirrhosis (thought in part to be due to high copper intake), starvation, after jejunoileal bypass surgery for morbid obesity, or after the use of certain drugs (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    or perhexiline). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38105?source=see_link\">",
"     \"Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mallory-Denk bodies do not appear to have a pathogenic role in the hepatic injury. However, their presence is an important marker of alcohol-induced injury. In a large, multicenter Veterans Administration study, Mallory-Denk bodies were detected in 76 percent of those with alcoholic hepatitis and in 95 percent of those who also had cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21162/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alcoholic fibrosis, like the other lesions seen in alcoholic liver disease, first appears in zone 3 and may progress to become panlobular, particularly in those who continue to drink [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21162/abstract/54\">",
"     54",
"    </a>",
"    ]. Early zone 3 fibrosis, also called hyaline necrosis, predicts a high likelihood of eventual cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21162/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. Since patients who abuse alcohol often deny having a drinking problem, the presence of zone 3 fibrosis can sometimes be used to convince a patient who drinks heavily that his or her drinking is a problem and that eventual progression to end-stage liver disease is virtually certain with continued alcohol abuse.",
"   </p>",
"   <p>",
"    The term \"fibrosis\" in this setting denotes the accumulation of scar or extracellular matrix (ECM), and is potentially reversible in the absence of continued alcohol abuse. By contrast, true cirrhosis (",
"    <a class=\"graphic graphic_picture graphicRef82544 graphicRef65537 \" href=\"UTD.htm?15/15/15610\">",
"     picture 3A-B",
"    </a>",
"    ) is characterized by the presence of regenerative nodules and is generally thought to be irreversible, even in the absence of further alcohol ingestion. Cirrhosis in alcoholic liver disease may be micronodular or macronodular [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21162/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. In addition, some patients with micronodular cirrhosis will later progress to macronodular cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21162/abstract/58\">",
"     58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23194?source=see_link&amp;anchor=H13#H13\">",
"     \"Diagnostic approach to the patient with cirrhosis\", section on 'Morphologic classification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are numerous causes of hepatic steatosis and cirrhosis other than alcoholic liver disease. In particular, nonalcoholic steatohepatitis should be considered since its clinical and histologic features are very similar to those seen in patients with alcoholic liver disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H73665151\">",
"    <span class=\"h2\">",
"     Differential diagnosis of hepatic steatosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of hepatic steatosis includes (",
"    <a class=\"graphic graphic_table graphicRef58924 \" href=\"UTD.htm?12/20/12619\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21162/abstract/34,59\">",
"     34,59",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Alcoholic liver disease",
"     </li>",
"     <li>",
"      Non-alcoholic liver disease",
"     </li>",
"     <li>",
"      Hepatitis C (particularly genotype 3)",
"     </li>",
"     <li>",
"      Wilson disease",
"     </li>",
"     <li>",
"      Lipodystrophy",
"     </li>",
"     <li>",
"      Starvation",
"     </li>",
"     <li>",
"      Parenteral nutrition",
"     </li>",
"     <li>",
"      Abetalipoproteinemia",
"     </li>",
"     <li>",
"      Medications (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"       tetracycline",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      , glucocorticoids,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      , anti-retroviral agents for HIV)",
"     </li>",
"     <li>",
"      Reye syndrome",
"     </li>",
"     <li>",
"      Acute fatty liver of pregnancy",
"     </li>",
"     <li>",
"      HELLP (hemolytic anemia, elevated liver enzymes, low platelet count) syndrome",
"     </li>",
"     <li>",
"      Inborn errors of metabolism (LCAT deficiency, cholesterol ester storage disease, Wolman disease)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some of these entities may be suggested by the patient's medical and social history. Other causes may be suspected based upon the patient's age, such as abetalipoproteinemia, Reye syndrome, and inborn errors of metabolism, which are seen in children, or Wilson disease, which is typically seen in patients under the age of 40 years. Other causes may be suggested by the physical examination, such as Kaiser-Fleisher rings in patients with Wilson disease.",
"   </p>",
"   <p>",
"    Based on the likelihood of a given diagnosis, specific testing can be performed to narrow the differential diagnosis. (See",
"    <a class=\"local\" href=\"#H62648107\">",
"     'Laboratory tests'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H73665204\">",
"    <span class=\"h2\">",
"     Differential diagnosis of cirrhosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many causes of chronic liver disease may result in cirrhosis, including chronic viral hepatitis, hemochromatosis, primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis. As with hepatic steatosis, a specific etiology for a patient's cirrhosis can often be determined through a combination of history, physical examination findings, and laboratory evaluation (",
"    <a class=\"graphic graphic_table graphicRef55647 \" href=\"UTD.htm?29/63/30716\">",
"     table 5",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23194?source=see_link&amp;anchor=H12#H12\">",
"     \"Diagnostic approach to the patient with cirrhosis\", section on 'Determining the cause of cirrhosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Differentiating alcoholic from non-alcoholic liver disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonalcoholic fatty liver disease (NAFLD) is the primary consideration in patients who deny alcohol abuse but have clinical features suggestive of alcoholic liver disease (such as elevated aminotransferases in the absence of serum markers of viral hepatitis).",
"   </p>",
"   <p>",
"    It can be difficult to distinguish NAFLD from alcoholic liver disease based upon clinical or histologic features. Some histologic features of NAFLD (such as macrovesicular steatosis and inflammation with Mallory-Denk bodies) are indistinguishable from alcoholic liver disease (",
"    <a class=\"graphic graphic_picture graphicRef51497 graphicRef75188 \" href=\"UTD.htm?38/20/39240\">",
"     picture 4A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21162/abstract/52,60\">",
"     52,60",
"    </a>",
"    ]. On the other hand, features more common in alcoholic liver disease than in NAFLD include canalicular cholestasis, marked ductular reaction, acute inflammation in the portal regions, and periportal fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21162/abstract/61\">",
"     61",
"    </a>",
"    ]. Steatosis is not always seen in alcoholic liver disease, whereas NAFLD is generally associated with a greater degree of steatosis and nuclear vacuolization.",
"   </p>",
"   <p>",
"    The presence of obesity does not help differentiate alcoholic from NAFLD. While obesity is a known risk factor for NAFLD, it can also increase the risk of developing steatosis in heavy drinkers [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21162/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A predictive model (the alcoholic liver disease to NAFLD index [ANI]) has been proposed to distinguish alcoholic from nonalcoholic liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21162/abstract/62\">",
"     62",
"    </a>",
"    ]. The model is based upon aminotransferase levels, mean corpuscular volume (MCV), body mass index (BMI), and sex:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;ANI = -58.5 + 0.637 (MCV) + 3.91",
"    <span class=\"nowrap\">",
"     (AST/ALT)",
"    </span>",
"    &ndash; 0.406 (BMI) + 6.35 for men",
"   </p>",
"   <p>",
"    An ANI greater than zero favors a diagnosis of alcoholic liver disease, whereas an ANI less than zero favors a diagnosis of NAFLD. The probability of the patient having alcoholic liver disease rather than NAFLD is then calculated using the value obtained for the ANI:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;Probability =",
"    <span class=\"nowrap\">",
"     e",
"     <sup>",
"      ANI",
"     </sup>",
"     /(1+e",
"     <sup>",
"      ANI",
"     </sup>",
"     )",
"    </span>",
"   </p>",
"   <p>",
"    The ability of the model to accurately categorize patients ranged from good to excellent in validation cohorts [",
"    <a class=\"abstract\" href=\"UTD.htm?20/42/21162/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The clinical manifestations of alcoholic liver disease depend on the severity of disease (",
"      <a class=\"graphic graphic_table graphicRef82583 \" href=\"UTD.htm?9/25/9627\">",
"       table 1",
"      </a>",
"      ). Patients with steatosis may have a normal examination or hepatomegaly. Patients who have developed cirrhosis may have stigmata of chronic liver disease (eg, spider angiomata, palmar erythema, gynecomastia). With hepatic decompensation, patients may develop ascites, peripheral edema, or hepatic encephalopathy. (See",
"      <a class=\"local\" href=\"#H1680453\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are several characteristic laboratory abnormalities in patients with alcoholic liver disease, but none is diagnostic (",
"      <a class=\"graphic graphic_table graphicRef64489 \" href=\"UTD.htm?37/57/38811\">",
"       table 2",
"      </a>",
"      ). The classic finding is moderately elevated transaminases, with an aspartate aminotransferase (AST) to alanine aminotransferase (ALT) ratio &gt;1 (and often &gt;2). (See",
"      <a class=\"local\" href=\"#H1681012\">",
"       'Laboratory tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ultrasound, computed tomography, and magnetic resonance imaging may demonstrate hepatic parenchymal changes, but they cannot confirm that the changes are the result of alcoholic liver disease (See",
"      <a class=\"local\" href=\"#H62649043\">",
"       'Imaging studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Alcoholic liver disease may be suspected in a patient with a compatible history who has elevated serum transaminases, a suggestion of fatty liver on imaging tests, or is found to have steatosis on liver biopsy. (See",
"      <a class=\"local\" href=\"#H76346509\">",
"       'When to consider alcoholic liver disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical and laboratory features are often adequate for establishing a diagnosis of alcoholic liver disease. Our general approach to the diagnosis of alcoholic liver disease is consistent with a 2010",
"      <a class=\"external\" href=\"file://www.aasld.org/practiceguidelines/Documents/Bookmarked Practice Guidelines/AlcoholicLiverDisease1-2010.pdf\">",
"       guideline",
"      </a>",
"      from the American Association for the Study of Liver Diseases and the American College of Gastroenterology (",
"      <a class=\"graphic graphic_table graphicRef63838 \" href=\"UTD.htm?25/32/26123\">",
"       table 3",
"      </a>",
"      ) and a 2012",
"      <a class=\"external\" href=\"file://www.easl.eu/assets/application/files/5e1b5512fb2cabb_file.pdf\">",
"       guideline",
"      </a>",
"      from the European Association for the Study of Liver. The evaluation includes (see",
"      <a class=\"local\" href=\"#H1680469\">",
"       'Diagnosis'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Obtaining a history to quantify alcohol use and identify other potential sources of hepatic injury. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'History'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Performing a physical examination to identify stigmata of chronic liver disease. (See",
"      <a class=\"local\" href=\"#H61973941\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Obtaining laboratory tests to look for signs of hepatitic inflammation and to assess hepatic synthetic function. (See",
"      <a class=\"local\" href=\"#H61974500\">",
"       'Standard laboratory evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Obtaining laboratory tests to identify other causes of hepatic injury. (See",
"      <a class=\"local\" href=\"#H61974447\">",
"       'Tests for other causes of liver disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A liver biopsy may be required if the diagnosis of alcoholic liver disease remains uncertain following a noninvasive evaluation. In addition, it can establish the severity of liver disease. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Liver biopsy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21162/abstract/1\">",
"      Bellentani S, Saccoccio G, Costa G, et al. Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos Study Group. Gut 1997; 41:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21162/abstract/2\">",
"      O'Shea RS, Dasarathy S, McCullough AJ, et al. Alcoholic liver disease. Hepatology 2010; 51:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21162/abstract/3\">",
"      European Association for the Study of Liver. EASL clinical practical guidelines: management of alcoholic liver disease. J Hepatol 2012; 57:399.",
"     </a>",
"    </li>",
"    <li>",
"     file://pubs.niaaa.nih.gov/publications/Surveillance93/Cirr09.htm (Accessed on November 28, 2012).",
"    </li>",
"    <li>",
"     file://www.who.int/substance_abuse/publications/global_alcohol_report/en/ (Accessed on November 28, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21162/abstract/6\">",
"      Edmondson HA, Peters RL, Frankel HH, Borowsky S. The early stage of liver injury in the alcoholic. Medicine (Baltimore) 1967; 46:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21162/abstract/7\">",
"      Naveau S, Giraud V, Borotto E, et al. Excess weight risk factor for alcoholic liver disease. Hepatology 1997; 25:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21162/abstract/8\">",
"      Crabb DW. Pathogenesis of alcoholic liver disease: newer mechanisms of injury. Keio J Med 1999; 48:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21162/abstract/9\">",
"      Lane BP, Lieber CS. Ultrastructural alterations in human hepatocytes following ingestion of ethanol with adequate diets. Am J Pathol 1966; 49:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21162/abstract/10\">",
"      Tang-Barton P, Vas W, Weissman J, et al. Focal fatty liver lesions in alcoholic liver disease: a broadened spectrum of CT appearances. Gastrointest Radiol 1985; 10:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21162/abstract/11\">",
"      Barrio E, Tom&eacute; S, Rodr&iacute;guez I, et al. Liver disease in heavy drinkers with and without alcohol withdrawal syndrome. Alcohol Clin Exp Res 2004; 28:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21162/abstract/12\">",
"      Deleuran T, Gr&oslash;nbaek H, Vilstrup H, Jepsen P. Cirrhosis and mortality risks of biopsy-verified alcoholic pure steatosis and steatohepatitis: a nationwide registry-based study. Aliment Pharmacol Ther 2012; 35:1336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21162/abstract/13\">",
"      Par&eacute;s A, Caballer&iacute;a J, Bruguera M, et al. Histological course of alcoholic hepatitis. Influence of abstinence, sex and extent of hepatic damage. J Hepatol 1986; 2:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21162/abstract/14\">",
"      Galambos JT. Natural history of alcoholic hepatitis. 3. Histological changes. Gastroenterology 1972; 63:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21162/abstract/15\">",
"      Alexander JF, Lischner MW, Galambos JT. Natural history of alcoholic hepatitis. II. The long-term prognosis. Am J Gastroenterol 1971; 56:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21162/abstract/16\">",
"      Bird GL, Williams R. Factors determining cirrhosis in alcoholic liver disease. Mol Aspects Med 1988; 10:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21162/abstract/17\">",
"      Gao B, Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology 2011; 141:1572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21162/abstract/18\">",
"      Jepsen P, Ott P, Andersen PK, et al. Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study. Hepatology 2010; 51:1675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21162/abstract/19\">",
"      Adachi M, Brenner DA. Clinical syndromes of alcoholic liver disease. Dig Dis 2005; 23:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21162/abstract/20\">",
"      Galambos JT. Alcoholic hepatitis: its therapy and prognosis. Prog Liver Dis 1972; 4:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21162/abstract/21\">",
"      Morgan MY. The prognosis and outcome of alcoholic liver disease. Alcohol Alcohol Suppl 1994; 2:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21162/abstract/22\">",
"      Diehl AM. Liver disease in alcohol abusers: clinical perspective. Alcohol 2002; 27:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21162/abstract/23\">",
"      Kazemi-Shirazi L, Veloso MP, Frommlet F, et al. Differentiation of nonalcoholic from alcoholic steatohepatitis: are routine laboratory markers useful? Wien Klin Wochenschr 2008; 120:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21162/abstract/24\">",
"      Morita Y, Ueno T, Sasaki N, et al. Comparison of liver histology between patients with non-alcoholic steatohepatitis and patients with alcoholic steatohepatitis in Japan. Alcohol Clin Exp Res 2005; 29:277S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21162/abstract/25\">",
"      Sorbi D, Boynton J, Lindor KD. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol 1999; 94:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21162/abstract/26\">",
"      Nyblom H, Berggren U, Balldin J, Olsson R. High AST/ALT ratio may indicate advanced alcoholic liver disease rather than heavy drinking. Alcohol Alcohol 2004; 39:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21162/abstract/27\">",
"      Diehl AM, Potter J, Boitnott J, et al. Relationship between pyridoxal 5'-phosphate deficiency and aminotransferase levels in alcoholic hepatitis. Gastroenterology 1984; 86:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21162/abstract/28\">",
"      Singh DK, Rastogi A, Sakhuja P, et al. Comparison of clinical, biochemical and histological features of alcoholic steatohepatitis and non-alcoholic steatohepatitis in Asian Indian patients. Indian J Pathol Microbiol 2010; 53:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21162/abstract/29\">",
"      Cohen JA, Kaplan MM. The SGOT/SGPT ratio--an indicator of alcoholic liver disease. Dig Dis Sci 1979; 24:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21162/abstract/30\">",
"      Moussavian SN, Becker RC, Piepmeyer JL, et al. Serum gamma-glutamyl transpeptidase and chronic alcoholism. Influence of alcohol ingestion and liver disease. Dig Dis Sci 1985; 30:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21162/abstract/31\">",
"      Das SK, Mukherjee S, Vasudevan DM, Balakrishnan V. Comparison of haematological parameters in patients with non-alcoholic fatty liver disease and alcoholic liver disease. Singapore Med J 2011; 52:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21162/abstract/32\">",
"      Van Ness MM, Diehl AM. Is liver biopsy useful in the evaluation of patients with chronically elevated liver enzymes? Ann Intern Med 1989; 111:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21162/abstract/33\">",
"      Liangpunsakul S, Chalasani N. What should we recommend to our patients with NAFLD regarding alcohol use? Am J Gastroenterol 2012; 107:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21162/abstract/34\">",
"      Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012; 142:1592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21162/abstract/35\">",
"      Lee M, Kowdley KV. Alcohol's effect on other chronic liver diseases. Clin Liver Dis 2012; 16:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21162/abstract/36\">",
"      Chapman RW, Morgan MY, Laulicht M, et al. Hepatic iron stores and markers of iron overload in alcoholics and patients with idiopathic hemochromatosis. Dig Dis Sci 1982; 27:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21162/abstract/37\">",
"      Palmentieri B, de Sio I, La Mura V, et al. The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis. Dig Liver Dis 2006; 38:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21162/abstract/38\">",
"      Saverymuttu SH, Joseph AE, Maxwell JD. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J (Clin Res Ed) 1986; 292:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21162/abstract/39\">",
"      Mathiesen UL, Franz&eacute;n LE, Aselius H, et al. Increased liver echogenicity at ultrasound examination reflects degree of steatosis but not of fibrosis in asymptomatic patients with mild/moderate abnormalities of liver transaminases. Dig Liver Dis 2002; 34:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21162/abstract/40\">",
"      Mortele KJ, Ros PR. Imaging of diffuse liver disease. Semin Liver Dis 2001; 21:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21162/abstract/41\">",
"      Rofsky NM, Fleishaker H. CT and MRI of diffuse liver disease. Semin Ultrasound CT MR 1995; 16:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21162/abstract/42\">",
"      Borra RJ, Salo S, Dean K, et al. Nonalcoholic fatty liver disease: rapid evaluation of liver fat content with in-phase and out-of-phase MR imaging. Radiology 2009; 250:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21162/abstract/43\">",
"      Okazaki H, Ito K, Fujita T, et al. Discrimination of alcoholic from virus-induced cirrhosis on MR imaging. AJR Am J Roentgenol 2000; 175:1677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21162/abstract/44\">",
"      Machann J, Thamer C, Stefan N, et al. Follow-up whole-body assessment of adipose tissue compartments during a lifestyle intervention in a large cohort at increased risk for type 2 diabetes. Radiology 2010; 257:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21162/abstract/45\">",
"      Longo R, Pollesello P, Ricci C, et al. Proton MR spectroscopy in quantitative in vivo determination of fat content in human liver steatosis. J Magn Reson Imaging 1995; 5:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21162/abstract/46\">",
"      Schlemmer HP, Sawatzki T, Sammet S, et al. Hepatic phospholipids in alcoholic liver disease assessed by proton-decoupled 31P magnetic resonance spectroscopy. J Hepatol 2005; 42:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21162/abstract/47\">",
"      Menon DK, Sargentoni J, Taylor-Robinson SD, et al. Effect of functional grade and etiology on in vivo hepatic phosphorus-31 magnetic resonance spectroscopy in cirrhosis: biochemical basis of spectral appearances. Hepatology 1995; 21:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21162/abstract/48\">",
"      Rubin E, Lieber CS. Alcohol-induced hepatic injury in nonalcoholic volunteers. N Engl J Med 1968; 278:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21162/abstract/49\">",
"      Lefkowitch JH. Morphology of alcoholic liver disease. Clin Liver Dis 2005; 9:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21162/abstract/50\">",
"      Christoffersen P, Braendstrup O, Juhl E, Poulsen H. Lipogranulomas in human liver biopsies with fatty change. A morphological, biochemical and clinical investigation. Acta Pathol Microbiol Scand A 1971; 79:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21162/abstract/51\">",
"      Denk H, Lackinger E. Cytoskeleton in liver diseases. Semin Liver Dis 1986; 6:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21162/abstract/52\">",
"      Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994; 107:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21162/abstract/53\">",
"      French SW, Nash J, Shitabata P, et al. Pathology of alcoholic liver disease. VA Cooperative Study Group 119. Semin Liver Dis 1993; 13:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21162/abstract/54\">",
"      Teli MR, Day CP, Burt AD, et al. Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. Lancet 1995; 346:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21162/abstract/55\">",
"      Worner TM, Lieber CS. Perivenular fibrosis as precursor lesion of cirrhosis. JAMA 1985; 254:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21162/abstract/56\">",
"      Nakano M, Worner TM, Lieber CS. Perivenular fibrosis in alcoholic liver injury: ultrastructure and histologic progression. Gastroenterology 1982; 83:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21162/abstract/57\">",
"      Pomier-Layrargues G, Kusielewicz D, Willems B, et al. Presinusoidal portal hypertension in non-alcoholic cirrhosis. Hepatology 1985; 5:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21162/abstract/58\">",
"      Fauerholdt L, Schlichting P, Christensen E, et al. Conversion of micronodular cirrhosis into macronodular cirrhosis. Hepatology 1983; 3:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21162/abstract/59\">",
"      Hautekeete ML, Degott C, Benhamou JP. Microvesicular steatosis of the liver. Acta Clin Belg 1990; 45:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21162/abstract/60\">",
"      Powell EE, Cooksley WG, Hanson R, et al. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990; 11:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21162/abstract/61\">",
"      Yeh MM, Brunt EM. Pathology of nonalcoholic fatty liver disease. Am J Clin Pathol 2007; 128:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/42/21162/abstract/62\">",
"      Dunn W, Angulo P, Sanderson S, et al. Utility of a new model to diagnose an alcohol basis for steatohepatitis. Gastroenterology 2006; 131:1057.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3617 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-E0FBF310BF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_42_21162=[""].join("\n");
var outline_f20_42_21162=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1686233\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17187132\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1680453\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1680526\">",
"      Signs and symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1680566\">",
"      Physical examination findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1681012\">",
"      Laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H62649244\">",
"      - Liver test abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H62649270\">",
"      - Hematologic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H62649296\">",
"      - Other abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H62649217\">",
"      Radiographic imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1680469\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H76346509\">",
"      When to consider alcoholic liver disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H61973941\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H62648107\">",
"      Laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H61974500\">",
"      - Standard laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H61974447\">",
"      - Tests for other causes of liver disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H62649043\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H62649741\">",
"      - Ultrasound",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H76345480\">",
"      - Computed tomography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H76345538\">",
"      - Magnetic resonance imaging and spectroscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H76346075\">",
"      - Other noninvasive methods to detect fibrosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Liver biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H73664414\">",
"      - Patients who may need a liver biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1683016\">",
"      - Histologic findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H73665151\">",
"      Differential diagnosis of hepatic steatosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H73665204\">",
"      Differential diagnosis of cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Differentiating alcoholic from non-alcoholic liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3617\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3617|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/18/20778\" title=\"figure 1\">",
"      Standard alcoholic drink PI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3617|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/26/30119\" title=\"picture 1\">",
"      ETOH and HCV Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/55/12153\" title=\"picture 2\">",
"      Acute fatty liver Trichrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/19/9526\" title=\"picture 3A\">",
"      Alcoholic steatohepatitis and cirrhosis - low power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/51/823\" title=\"picture 3B\">",
"      Alcoholic steatohepatitis and cirrhosis II - low power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/57/7059\" title=\"picture 4A\">",
"      NASH Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/52/34628\" title=\"picture 4B\">",
"      Mallory body alcohol hepatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3617|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/25/9627\" title=\"table 1\">",
"      Physical findings ETOH abuse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/57/38811\" title=\"table 2\">",
"      Labs in ETOH liver disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/32/26123\" title=\"table 3\">",
"      Dx of alcoholic liver disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/20/12619\" title=\"table 4\">",
"      Causes of fatty liver",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/63/30716\" title=\"table 5\">",
"      Evaluation of cirrhosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/22/2409?source=related_link\">",
"      Alcohol abuse and dependence: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4710?source=related_link\">",
"      Alcohol abuse and hematologic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/53/35672?source=related_link\">",
"      Alcoholic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/4/28744?source=related_link\">",
"      Alcoholic hepatitis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/43/698?source=related_link\">",
"      Alcoholic hepatitis: Natural history and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/18/34090?source=related_link\">",
"      Approach to the patient with abnormal liver biochemical and function tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/13/30935?source=related_link\">",
"      Clinical manifestations and diagnosis of chronic pancreatitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/22/34153?source=related_link\">",
"      Clinical manifestations and diagnosis of hepatic encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/63/22521?source=related_link\">",
"      Clinical manifestations and diagnosis of primary sclerosing cholangitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13018?source=related_link\">",
"      Clinical manifestations, diagnosis, and natural history of Wilson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/8/6281?source=related_link\">",
"      Clinical manifestations, diagnosis, and natural history of alpha-1 antitrypsin deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41641?source=related_link\">",
"      Clinical manifestations, diagnosis, and natural history of primary biliary cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26520?source=related_link\">",
"      Diagnosis of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23194?source=related_link\">",
"      Diagnostic approach to the patient with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19353?source=related_link\">",
"      Enzymatic measures of cholestasis (eg, alkaline phosphatase, 5&rsquo;-nucleotidase, gamma-glutamyl transpeptidase)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38105?source=related_link\">",
"      Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/43/14010?source=related_link\">",
"      Evaluation of adults with ascites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/50/29482?source=related_link\">",
"      Hepatorenal syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/2/5160?source=related_link\">",
"      Liver transplantation in alcoholic liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/59/30650?source=related_link\">",
"      Noninvasive assessment of hepatic fibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/24/40328?source=related_link\">",
"      Overview of the chronic neurologic complications of alcohol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17337?source=related_link\">",
"      Overview of the complications, prognosis, and management of cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/61/38874?source=related_link\">",
"      Overview of the risks and benefits of alcohol consumption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/5/30807?source=related_link\">",
"      Pathogenesis of alcoholic liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40650?source=related_link\">",
"      Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/19/35129?source=related_link\">",
"      Pathophysiology and diagnosis of iron overload syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5446?source=related_link\">",
"      Patterns of plasma aspartate and alanine aminotransferase levels with and without liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22104?source=related_link\">",
"      Prognosis and management of alcoholic fatty liver disease and alcoholic cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/24/25993?source=related_link\">",
"      Screening for unhealthy use of alcohol and other drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24022?source=related_link\">",
"      Tests of the liver's biosynthetic capacity (eg, albumin, coagulation factors, prothrombin time)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/37/9814?source=related_link\">",
"      Transjugular liver biopsy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_42_21163="Initial hx endometriosis adoles";
var content_f20_42_21163=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F76235&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F76235&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Initial history",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       Characteristics of the pain: Location (diffuse or localized, if so where?), onset sudden or gradual, constant or intermittent, magnitude, timing, duration, quality (sharp or dull), radiation, relationship to various activities (physical, sexual, physiologic, menses)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Is pain associated with symptoms such as dysuria, urinary frequency, nausea, vomiting, chills, fever, backache or other musculoskeletal pain, or change in bowel habits?",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Past medical/surgical history with attention to symptoms suspicious for, diagnosis of, and therapy for endometriosis or pelvic inflammatory disease (PID), gastrointestinal (GI) or genitourinary (GU) problems, infection, musculoskeletal problems, or psychiatric conditions. Any previous diagnostic tests or treatments for pain?",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Menstrual, contraceptive, sexual, and gynecologic history",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Is there a history of sexual or substance abuse?",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Family history of relevant clinical conditions",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       How does pain interfere with daily activities?",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Does anything make the pain better or worse?",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Gambone, JC, Mittman, BS, Munro, MG, et al. Fertil Steril 2002; 78:961.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_42_21163=[""].join("\n");
var outline_f20_42_21163=null;
var title_f20_42_21164="Use antidepressants adol";
var content_f20_42_21164=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F62951&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F62951&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Use of antidepressants in children and adolescents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Evaluation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Consider antidepressant for patients with moderate to severe depression, or recurrent depressive episodes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Consider antidepressant for patients who have family members with positive response to SSRI antidepressant (and screen if family members had negative response/side effects to SSRIs)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Screen for potential bipolar disorder",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Family history of bipolar disorder, pressured speech, lack of sleep, impulsivity, patient initially presents suddenly very depressed out of the blue, excessive sleeping, very slowed down",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Review potential risk for increased agitation, suicidal ideation, and clarify importance of contacting physician if any thoughts of harm to self or others emerge",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Review SSRI Discontinuation syndrome if medication is stopped abruptly (dizziness, paresthesias, nausea, increased irritability)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Have patient and family sign consent (can obtain form from www.aacap.org)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Follow-Up",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If not feasible to meet weekly, ensure patient and family know how to contact physician if any thoughts of harm to self or others emerge, or if patient becomes more agitated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Review symptoms",
"        <strong>",
"         AND",
"        </strong>",
"        provide side effect scale (download free from www.schoolpsychiatry.org) and rating scales",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Create reasonable expectations (time line of medication response can take four to six weeks, if taken consistently)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Establish realistic outcome measures with patient (medication will improve sadness, ruminations, but will not make patient \"mind\" better, or no longer argue about curfew/bedtime)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Counsel adolescent about risks of substance use, especially alcohol, when depressed and on medication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Consider safety issues in the home (availability of dangerous medications, weapons) and provide phone number to access emergency psychiatric services",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Rappaport, N, Bostic, JQ, Prince JB, Jellinek, M. Treating pediatric depression in primary care: Coping with the patients' blue mood and the FDA's black box. J Pediatr 2006; 148:567. Copyright &copy;2006 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_42_21164=[""].join("\n");
var outline_f20_42_21164=null;
var title_f20_42_21165="Panitumumab monotherapy CRC";
var content_f20_42_21165=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F86309&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F86309&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Panitumumab monotherapy for metastatic, K-ras wild type colorectal cancer",
"    <sup>",
"     [1]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td colspan=\"4\">",
"        Cycle length: 2 weeks.",
"        <br/>",
"        Duration: Continue until disease progression or unacceptable toxicity.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose and route",
"       </td>",
"       <td class=\"subtitle1\">",
"        Administration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Given on days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Panitumumab",
"        </strong>",
"       </td>",
"       <td>",
"        6 mg/kg IV",
"       </td>",
"       <td>",
"        Dilute to total volume 100 mL with normal saline*. Administer over 60 minutes",
"        <sup>",
"         &Delta;",
"        </sup>",
"        using a low-protein-binding 0.2 micrometer or 0.22 micrometer in-line filter.",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Pretreatment considerations:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Emesis risk:",
"        </strong>",
"        LOW. Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Prophylaxis for infusion reactions:",
"        </strong>",
"        Routine premedication not indicated. Refer to UpToDate topic on \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Monitoring parameters:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Assess basic metabolic panel (including creatinine, magnesium, calcium, and potassium) prior to each dose. Monitor calcium, magnesium and potassium levels weekly for eight weeks after completion of therapy and institute appropriate treatment as needed",
"        <sup>",
"         [2]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Monitor for skin rash and for evidence of keratitis or ulcerative keratitis.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Monitor for diarrhea.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Assess for signs/symptoms of pulmonary toxicity.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Suggested dose alterations for toxicity:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Ocular toxicities:",
"        </strong>",
"        Interrupt or discontinue panitumumab for acute or worsening keratitis",
"        <sup>",
"         [2]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Infusion reactions:",
"        </strong>",
"        Reduce infusion rate by 50 percent for mild or moderate (grade 1 and 2) reactions and terminate the infusion for severe infusion reactions. Depending on the severity and/or persistence of the reaction, permanently discontinue panitumumab",
"        <sup>",
"         [2]",
"        </sup>",
"        . Refer to UpToDate topic on \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Dermatologic toxicity:",
"        </strong>",
"        Withhold therapy for severe or intolerable toxicity; may resume at 50 percent of dose if toxicity improves and escalate dose as tolerated for subsequent infusions",
"        <sup>",
"         [2]",
"        </sup>",
"        . Refer to UpToDate topic on \"",
"        <span class=\"emphasis\">",
"         Acneiform eruption secondary to epidermal growth factor (EGFR) inhibitors",
"        </span>",
"        \".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Pulmonary toxicity:",
"        </strong>",
"        Permanently discontinue panitumumab in patients developing pulmonary fibrosis/interstitial lung disease",
"        <sup>",
"         [2]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         If there is a change in body weight of at least 10 percent, doses should be recalculated.",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"    </strong>",
"    <div class=\"footnotes\">",
"     IV: intravenous.",
"     <br/>",
"     * Doses higher than 1000 mg should be diluted to 150 mL with normal saline and administered over 90 rather than 60 minutes.",
"     <br/>",
"     &Delta; If initial dose is well tolerated, subsequent doses can be administered over 30 minutes.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Van Cutsem E, et al. J Clin Oncol 2007; 25:1658.",
"       </li>",
"       <li>",
"        Vectibix (panitumumab) injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on June 8, 2012).",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_42_21165=[""].join("\n");
var outline_f20_42_21165=null;
var title_f20_42_21166="Evaluation and management of congenital syphilis in neonates";
var content_f20_42_21166=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F80812&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F80812&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Evaluation and management of neonates (&lt;1 month) born to women with syphilis or history of syphilis*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Initial neonatal evaluation",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Maternal treatment",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Subsequent neonatal evaluation",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Treatment of neonate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Neonate VDRL/RPR",
"       </td>",
"       <td class=\"subtitle2\">",
"        Neonate evaluation",
"       </td>",
"       <td class=\"subtitle2\">",
"        Timing",
"       </td>",
"       <td class=\"subtitle2\">",
"        Type",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Any result",
"       </td>",
"       <td>",
"        <span style=\"color: #ff0000;\">",
"         Examination compatible with congenital syphilis or visualization of spirochete in clinical specimen",
"         <sup>",
"          &bull;",
"         </sup>",
"        </span>",
"       </td>",
"       <td>",
"        Any",
"       </td>",
"       <td>",
"        Any or none",
"       </td>",
"       <td>",
"        <p>",
"         - CSF VDRL, cell count, protein",
"        </p>",
"        <p>",
"         - CBC with differential and platelet count",
"        </p>",
"        <p>",
"         - Additional tests as clinically indicated",
"         <sup>",
"          &Delta;",
"         </sup>",
"        </p>",
"       </td>",
"       <td>",
"        10 days of parenteral penicillin",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <span style=\"color: #ff0000;\">",
"         &ge; Fourfold maternal titer",
"        </span>",
"       </td>",
"       <td>",
"        Any",
"       </td>",
"       <td>",
"        Any",
"       </td>",
"       <td>",
"        Any",
"       </td>",
"       <td>",
"        <p>",
"         - CSF VDRL, cell count, protein",
"        </p>",
"        <p>",
"         - CBC with differential and platelet count",
"        </p>",
"        <p>",
"         - Additional tests as clinically indicated",
"         <sup>",
"          &Delta;",
"         </sup>",
"        </p>",
"       </td>",
"       <td>",
"        10 days of parenteral penicillin",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Nonreactive",
"       </td>",
"       <td>",
"        Normal physical examination",
"       </td>",
"       <td>",
"        During pregnancy",
"       </td>",
"       <td>",
"        Adequate",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        None;",
"        <sup>",
"        </sup>",
"        some experts would treat with a single dose of IM benzathine penicillin",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Nonreactive",
"       </td>",
"       <td>",
"        Normal physical examination",
"       </td>",
"       <td>",
"        During pregnancy",
"       </td>",
"       <td>",
"        None, inadequate, suboptimal",
"        <sup>",
"         ",
"        </sup>",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Single dose IM benzathine penicillin",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        &lt; Fourfold maternal titer",
"       </td>",
"       <td>",
"        Normal physical examination",
"       </td>",
"       <td>",
"        During pregnancy",
"       </td>",
"       <td>",
"        Adequate",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Single dose IM benzathine penicillin",
"        <sup>",
"         &yen;",
"        </sup>",
"        ; some experts would not treat but provide close serologic follow-up",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        &lt; Fourfold maternal titer",
"       </td>",
"       <td>",
"        Normal physical examination",
"       </td>",
"       <td>",
"        During pregnancy",
"       </td>",
"       <td>",
"        None, inadequate, suboptimal",
"        <sup>",
"         ",
"        </sup>",
"       </td>",
"       <td>",
"        <p>",
"         - CSF VDRL, cell count, protein",
"        </p>",
"        <p>",
"         - CBC with differential and platelet count",
"        </p>",
"        <p>",
"         - Additional tests as clinically indicated",
"         <sup>",
"          &Delta;",
"         </sup>",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         If the entire evaluation is performed and normal",
"         <sup>",
"          ",
"         </sup>",
"         : Single dose IM benzathine penicillin",
"         <sup>",
"          &yen;",
"         </sup>",
"         ; some experts would treat with 10 days of parenteral penicillin",
"         <sup>",
"          &loz;",
"         </sup>",
"        </p>",
"        <p>",
"         If any portion of the evaluation is abnormal, not performed, or not interpretable: 10 days of parenteral penicillin",
"         <sup>",
"          &loz;",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        &lt; Fourfold maternal titer",
"       </td>",
"       <td>",
"        Normal physical examination",
"       </td>",
"       <td>",
"        Before pregnancy",
"       </td>",
"       <td>",
"        Adequate",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        None; some experts would treat with a single dose of IM benzathine penicillin",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        &lt; Fourfold maternal titer",
"       </td>",
"       <td>",
"        Normal physical examination",
"       </td>",
"       <td>",
"        Before pregnancy",
"       </td>",
"       <td>",
"        Evidence of reinfection or relapse (&ge; fourfold increase in post-treatment titer)",
"       </td>",
"       <td>",
"        <p>",
"         - CSF VDRL, cell count, protein",
"        </p>",
"        <p>",
"         - CBC with differential and platelet count",
"        </p>",
"        <p>",
"         - Additional tests as clinically indicated",
"         <sup>",
"          &Delta;",
"         </sup>",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         If the entire evaluation is performed and normal: Single dose IM benzathine penicillin",
"         <sup>",
"          &yen;",
"         </sup>",
"        </p>",
"        <p>",
"         If any portion of the evaluation is abnormal, not performed, or not interpretable: 10 days of parenteral penicillin",
"         <sup>",
"          &loz;",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Neonate characteristics in",
"    <span style=\"color:#ff0000\">",
"     red text",
"    </span>",
"    indicate proven or highly probable congenital syphilis disease in the infant.",
"    <div class=\"footnotes\">",
"     VDRL: Venereal Disease Research Laboratory serologic test for syphilis; RPR: rapid plasma reagin serologic test for syphilis; CSF: cerebrospinal fluid; CBC: complete blood count; IM: intramuscular; IV: intravenous.",
"     <br>",
"      * Mother with reactive nontreponemal (VDRL or RPR) and treponemal (microhemagglutination test for",
"      <em>",
"       T. pallidum",
"      </em>",
"      [MHA-TP] or fluorescent treponemal antibody absorption [FTA-ABS]) serologic tests for syphilis. All such infants require clinical and serologic follow-up (see text for details).",
"      <br>",
"       <font class=\"bullet\">",
"        &bull;",
"       </font>",
"       Examination findings compatible with early congenital syphilis may include (but are not limited to) hepatomegaly/hepatosplenomegaly; rash; condyloma lata; snuffles; jaundice; pseudoparalysis; anemia; and edema.",
"       <br>",
"        &Delta; Additional tests may include: long-bone radiographs, chest radiograph, liver function tests, cranial ultrasonography, ophthalmologic examination, and auditory brainstem response.",
"        <br>",
"         <font class=\"lozenge\">",
"          &loz;",
"         </font>",
"         There are two alternate regimens: Aqueous penicillin G (50,000 units/kg IV every 12 hours [for infants &le;7 days of age] and every 8 hours [&gt;7 days of age] for a total of 10 days); or procaine penicillin G 50,000 units/kg IM as a single daily dose for 10 days.",
"         <br>",
"          &sect; Adequate therapy encompasses treatment with penicillin more than four weeks before delivery; appropriate dose for the stage of disease; documentation of treatment response (fourfold decline in titer for early syphilis and titer remained stable or low [VDRL &le;1:2; RPR &le;1:4] for late syphilis); no evidence of reinfection or relapse (fourfold increase in titer after treatment).",
"          <br>",
"           &yen; Benzathine penicillin G (50,000 units/kg intramuscularly as a single dose).",
"           <br>",
"            &Dagger; Inadequate or suboptimal maternal therapy encompasses: treatment with a nonpenicillin antibiotic; treatment less than four weeks before delivery; inappropriate dose for the stage of disease; no documentation of maternal therapy; maternal titers did not decline at least fourfold after treatment for early syphilis or did not remain stable and low [VDRL &le;1:2; RPR &le;1:4] for late syphilis; or maternal titers increased by fourfold after treatment (suggesting reinfection or relapse).",
"            <br>",
"             &dagger; Normal CSF is generally defined by nonreactive VDRL, CSF WBC &lt;25 cells/microL, and CSF protein &lt;150 mg/dL for term infants and &lt;170 mg/dL for preterm infants; however, some experts define normal CSF WBC as &lt;5 cells/microL and normal CSF protein as &lt;40 mg/dL.",
"            </br>",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <br>",
"       1. Workowski KA, Berman S, Centers for Disease Control and Prevention, et al. Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010; 59:1.",
"       <br>",
"        2. American Academy of Pediatrics. Syphilis. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th ed, Pickering LK (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.690.",
"        <br>",
"         3. Dobson SR, Sanchez PJ. Syphilis. In: Textbook of Pediatric Infectious Diseases, 6th ed, Feigin RD, Cherry JD, Demmler-Harrison GJ, Kaplan SL (Eds), Saunders, Philadelphia 2009. p.1826.",
"         <br>",
"          4. Kollmann TR, Dobson SD. Syphilis. In: Infectious Diseases of the Fetus and Newborn infant, 7th edition, Remington JS, Klein JO, Wilson CB, et al (Eds), Elsevier Saunders, Philadelphia 2011. p.524.",
"          <br/>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_42_21166=[""].join("\n");
var outline_f20_42_21166=null;
var title_f20_42_21167="Evaluation for LGL";
var content_f20_42_21167=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F80765&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F80765&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 545px\">",
"   <div class=\"ttl\">",
"    Suggested algorithm for the evaluation of large granular lymphocyte leukemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 525px; height: 542px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * In case of strong clinical suspicion, phenotyping is recommended as typical LGL phenotype is sometimes observed in the absence of LGL morphology.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced by permission from Cancer Control: Journal of the Moffitt Cancer Center. Lamy, T, Loughran, TP Jr. Large granular lymphocyte leukemia. Cancer Control 1998; 5:25.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_42_21167=[""].join("\n");
var outline_f20_42_21167=null;
